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Diffuse large B-cell lymphoma (DLBCL) can be categorized into two clinically relevant 
subtypes: activated B-cell (ABC) DLBCL and germinal center B-cell (GCB).  Patients with ABC 
DLBCL have a worse prognosis, and are defined by chronic, overactive signaling through the B-
cell receptor and NF-κB pathways.  Signaling through the B-cell receptor is heavily dependent 
on the Src family kinases (SFKs), and NF-κB signaling is dependent on the proteasome. 
In Chapters 2 and 3, we examined the effects of the SFK inhibitor dasatinib in a panel of 
ABC and GCB DLBCL cell lines, with a focus on changes in the kinome (Chapter 2) or the 
proteasome (Chapter 3).  In Chapter 2, we found that the ABC DLBCL cell lines are much more 
sensitive to dasatinib than the GCB DLBCL cell lines.  However, both subtypes display 
inhibition of the SFKs in response to dasatinib treatment.  Subsequent analyses revealed several 
cell cycle kinases to be inhibited by dasatinib treatment in the ABC DLBCL subtype, but not in 
the GCB DLBCL subtype.  In Chapter 3, we found that treatment with dasatinib results in a 
decrease in the proteasome’s chymotrypsin-like (ChL), trypsin-like (TL), and caspase-like (CaL) 
activities in the ABC but not GCB DLBCL cell lines.  Furthermore, it appears that association 
between the proteasome 20S core particle and 19S regulatory particle is disrupted in the ABC 
DLBCL cell lines after dasatinib treatment. 
iv 
In Chapter 4, we explored the utility of site-specific inhibitors of the proteasome’s TL 
and CaL activities in a variety of cancer cell lines.  We found that the TL/ChL and CaL/ChL 
ratios of proteasome activity correlate with sensitivity to TL and CaL inhibitors, respectively.  In 
addition, the two hematological malignancy cell lines studied are most sensitive to the site-
specific inhibitors.  Furthermore, the combination of the TL or CaL site-specific inhibitors with 
bortezomib or carfilzomib is synergistic in all cell lines examined. 
The studies presented in this thesis have important implications for the clinical use of 
dasatinib and site-specific proteasome inhibitors for the treatment of DLBCL, either alone or in 
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CHAPTER 1: INTRODUCTION1 
 
 
1.1 Diffuse Large B-cell Lymphoma 
Lymphomas and leukemias are cancers of the immune system, with lymphomas generally 
presenting as solid tumors of immune cells in lymph nodes and leukemias generally presenting 
as overgrowths of immune cells in the blood or bone marrow.  Roughly 90% of lymphomas are 
classified as Non-Hodgkin lymphoma (NHL), which is the seventh most common cancer in the 
United States (1-3).  Non-Hodgkin lymphoma can be further categorized into several different 
subtypes, with diffuse large B-cell lymphoma (DLBCL) comprising roughly one-third of NHLs 
(2,3).  Despite DLBCL being the most common subtype of NHL, there is still a lot of 
heterogeneity within this disease. 
By gene expression profiling, DLBCL patients can be categorized into two clinically 
relevant subtypes: activated B-cell (ABC) and germinal center B-cell (GCB) (4).  Patients with 
ABC DLBCL generally have much shorter (poorer) median overall survival time and 
progression-free survival time than those with GCB DLBCL (5,6).  Despite these distinctions, 
there are currently no significant treatment differences between these two subtypes.  The 
standard treatment of DLBCL is a cocktail of chemotherapeutic agents called R-CHOP, which 
includes the following compounds: rituximab, an anti-CD20 antibody; cyclophosphamide, a 
DNA alkylating agent; doxorubicin (also known as hydroxydaunorubicin), a DNA intercalating 
                                                 
1 Section 1.5 of this chapter previously appeared as an article in the Journal of Cellular Biochemistry.  The original 
citation is as follows: 
Cann ML, McDonald IM, East MP, Johnson GL, Graves LM. Measuring Kinase Activity – A Global Challenge. J 
Cell Biochem. 2017 Nov;118(11):3595-3606. 
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agent; vincristine (brand name Oncovin), a microtubule polymerization inhibitor; and 
prednisone, an immune suppressant.  However, roughly 10% of DLBCL patients will be 
refractory (non-responsive) to this therapy, and a substantial 40% of DLBCL patients who do 
respond to R-CHOP will relapse within 5 years (7).  Although the standard R-CHOP 
chemotherapy regimen has a relatively high cure rate for patients with a good prognosis (2,8), 
patients with refractory and relapsed DLBCL pose a significant challenge to effective treatment. 
The CHOP backbone of the R-CHOP cocktail has been in use since the 1970s, and 
rituximab was added as part of the cocktail in the early 2000s.  In an era where personalized 
medicine is gaining recognition as a means for treating cancer, it is surprising that recent 
advances in the treatment of DLBCL have been limited.  Chronic, overactive signaling through 
the B-cell receptor (BCR) and the anti-apoptotic NF-κB pathway are hallmarks of the ABC but 
not the GCB DLBCL subtype (9,10), and could therefore be particularly important for promoting 
tumor progression and drug resistance.  In fact, several therapies targeting aspects of these 
pathways are currently under investigation in clinical trials for the treatment of DLBCL, 
including bortezomib (proteasome inhibitor) (11,12), ibrutinib (Btk inhibitor) (13), fostamatinib 
(Syk inhibitor) (14), lenalidomide (immunomodulatory agent) (15), enzastaurin (PKCβ inhibitor) 
(16), ruxolitinib (Janus kinase inhibitor) (17), and idelalisib (PI3K inhibitor) (18).  Although 
some of these therapeutic agents have shown preferential activity in the poorly-prognosed ABC 
subtype (19,20), none of these agents are FDA-approved for use in DLBCL.  A better 
understanding of the cellular processes that contribute to tumor progression and drug resistance 
in DLBCL would complement ongoing studies of promising therapeutic agents and could lead to 
the identification of additional therapeutic targets for the treatment of relapsed and refractory 
DLBCL. 
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1.2 The Src Family Kinases (SFKs) 
Kinases are crucial cellular signaling enzymes that catalyze the transfer of a phosphoryl 
group from ATP to amino acid residues on protein substrates.  They are categorized based on the 
amino acid residues they phosphorylate: serine/threonine kinases or tyrosine kinases.  The 
tyrosine kinases can be further categorized based on whether they can also function as receptors 
(receptor tyrosine kinases) or not (nonreceptor tyrosine kinases). 
The Src family kinases (SFKs) are a family of nine nonreceptor tyrosine kinases that 
include Blk, Hck, Fgr, Frk, Fyn, Lck, Lyn, Src, and Yes in mammals (21,22) (Table 1.1).  The 
prototypical family member, Src, was discovered in the 1970s as the first molecularly-defined 
proto-oncogene.  Mutations of the Src gene were captured in the genome of the avian Rous 
sarcoma virus, giving rise to the oncogene v-Src (23,24).  This gene was identified as the 
transforming protein of the oncogenic Rous sarcoma virus, which caused tumor growth in 
chickens (21,22).  Later, the evidence that the Src protein possesses tyrosine kinase activity 
launched a search for related protein kinases, and the additional members of the SFKs were 
discovered (23).  Many subsequent studies of the SFKs demonstrated that these kinases play a 
role in a multitude of cellular signaling pathways (21-25). 
The SFKs can be subdivided into three groups, based their expression patterns.  Src, Fyn, 
and Yes are expressed in most tissues (23).  A second group including Blk, Fgr, Hck, Lck, and 
Lyn are primarily found in hematopoietic cells (26).  Lastly, Frk is primarily expressed in 
epithelial-derived cells (22).  Despite differences in expression, the SFKs are highly related to 
one another and have significant sequence homology.  Each of the SFK members have four key 
Src homology (SH) domains: SH1, the kinase domain; SH2, a phospho-tyrosine binding domain; 
SH3, a domain that binds proline-rich amino acid sequences; and SH4, which contains a 
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myristoylation site important for membrane anchoring (21,22) (Figure 1.1).  In addition to these 
domains, each SFK member has a C-terminal tail, containing an autoinhibitory tyrosine 
phosphorylation site, and a unique N-terminal region whose function remains unclear.  The 
structure of the SH1 kinase domain of the SFKs is comparable to that of most kinases, and is 
composed of an N-terminal lobe and a C-terminal lobe (27).  The binding of ATP and the 
transfer of the phosphoryl group occur at the cleft between these two lobes.  The C-terminal lobe 
contains the substrate binding site and an activation loop (27), another common feature of 
kinases. 
Within the aforementioned domains, there are two key regulatory phosphorylation sites: 
Tyr416 in the kinase domain activation loop and Tyr527 on the C-terminal tail (21,22).  
Although the amino acid number of each phosphorylation site differs slightly among the various 
SFK members, the nomenclature refers to them based on the amino acid numbers of the first 
SFK member to be identified, chicken Src.  Phosphorylation of Tyr527 by Csk is known to be 
autoinhibitory (21-23).  Phosphorylation of Tyr527 causes binding of the C-terminal tail by the 
SH2 domain, a conformational change that also favors binding of the kinase domain by the SH3 
domain, leading to a tightly bound closed configuration that covers the kinase domain and 
reduces its potential for substrate interaction (28).  In contrast, dephosphorylation of Tyr527 
weakens the intramolecular interactions and allows for autophosphorylation at Tyr416.  This 
autophosphorylation helps activate the kinase, opening the protein and freeing the SH2 and SH3 
domains to interact with SFK binding partners and substrates.  Activity of the SFKs is commonly 
measured by simply examining the levels of phospho-Tyr416 (active) and phospho-Tyr527 
(inactive) SFK.  It should be noted that, due to the high level of sequence homology between 
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SFK members, antibodies that target these phosphorylation sites are unlikely to differentiate 
between SFK members. 
 
1.3 The SFKs and B-cell Receptor (BCR) Signaling 
Upon activation, the SFKs are involved in a multitude of normal cellular processes, such 
as proliferation, survival, motility and adhesion, differentiation, and more (21-25,29).  They are 
key mediators of signaling through immune recognition receptors, several receptor tyrosine 
kinases, integrins, and even some G-protein coupled receptors (22).  Some examples of SFK 
substrates are Syk, Abl, cyclins D and E, focal adhesion kinase (FAK), members of the MAPK 
pathway, phospholipase C γ (PLC γ), and signal transducers and activators of transcription 
(STATs) (22,23,30,31). 
In the context of B-cells, the SFKs are key mediators of B-cell receptor (BCR) signaling 
(32-34) (Figure 1.2).  The BCR is composed of membrane immunoglobulin (mIg) molecules 
associated with Igα and Igβ (also known as CD79a and CD79b) heterodimers.  Under resting 
conditions, the SFKs are anchored to the plasma membrane and weakly interact with the Igα/Igβ 
heterodimers (35).  Upon binding of antigen, BCRs will aggregate and induce a conformational 
change in the Igα/Igβ proteins that promotes phosphorylation of their immunoreceptor tyrosine-
based activation motifs (ITAMs) by the SFKs, namely Lyn (36).  Phosphorylation of the ITAMs 
promotes recruitment of the nonreceptor tyrosine kinase Syk, which becomes active upon 
binding (33,34).  Activated Syk can then phosphorylate the nonreceptor tyrosine kinase Btk.  
This ordered activation of the Lyn (or other SFKs), Syk, and Btk is required for proper BCR 
signal transduction, and leads to the activation of many different pathways, including the 
PI3K/Akt, NF-κB, and MAPK pathways (32). 
6 
1.4 Role of the SFKs in Cancer and Lymphoma 
The SFKs play a role in signaling from many receptors, facilitating several proliferation, 
survival, and cell motility pathways (22,23,29).  Based on SFK involvement in these signaling 
pathways, it is not surprising that the SFKs have been implicated in progression and drug 
resistance in many cancers, including lymphoma (9,29,37,38).  Interestingly, many of the 
pathways in which the SFKs play a role are the types of pathways often found to be aberrant in 
cancer cells (39).  Although much of the aberrant signaling observed in cancer cells can be 
attributed to gene mutations, the SFKs are rarely mutated in cancer (40-43).  Rather, they are 
often found to have higher activity or be more highly expressed in several cancers (44).  For 
example, Src, Lyn, and Fgr are expressed at high levels in malignant tissues and primary cell 
cultures derived from the prostate (45,46), and increased Src activity is correlated with more 
invasive forms of prostate cancer (47).  Other studies have heavily implicated Src and Yes in the 
progression of colorectal cancer (48,49).  The SFKs have also been implicated in breast, lung, 
head and neck, and pancreatic cancer (29).  In the context of hematological malignancies, there is 
increasing evidence that Lyn and other SFK members play a role in several types of leukemia 
and lymphoma, including DLBCL (37,50-56).  For example, Lyn is often found to be 
overexpressed and/or overactive in chronic myelogenous leukemia cells with the Bcr-Abl 
mutation (52,56,57). 
As described earlier, chronic, overactive signaling through the B-cell receptor (BCR) and 
the anti-apoptotic NF-κB pathway are hallmarks of the ABC but not the GCB DLBCL subtype 
(9,10), and could therefore be particularly important for promoting tumor progression and drug 
resistance.  Signaling through the BCR triggers the activation of many pro-survival and anti-
apoptotic signaling pathways, including the anti-apoptotic NF-κB pathway.  Important mediators 
7 
of BCR signaling are Syk and Btk, both of which have inhibitors in clinical trials for the 
treatment of DLBCL as well as other types of lymphoma (58).  The importance of activation of 
Lyn (or other SFKs), Syk, and Btk for BCR signaling is well known, and deficiencies in any one 
of these tyrosine kinases results in defective or aberrant B-cell function and development (59-
61).  Therefore, it stands to reason that SFK inhibition in the context of ABC DLBCL may 
provide a valuable option for the treatment of this disease. 
 Unsurprisingly, the significant amount of evidence that implicates the SFKs in cancer 
progression has led to the development and exploration of many SFK inhibitors.  Perhaps the 
most notable SFK inhibitor is BMS-354825, or dasatinib (Sprycel, Figure 1.3A).  Dasatinib is a 
dual SFK/Abl inhibitor (62), and was initially pursued in clinical trials to overcome resistance to 
the Bcr-Abl inhibitor imatinib (Gleevec) in chronic myelogenous leukemia (CML) (63).  Like 
many kinase inhibitors, dasatinib is a rather nonspecific kinases inhibitor, but its primary targets 
are the SFKs and Bcr-Abl (64).  Despite this promiscuity, dasatinib is FDA-approved for the 
treatment of CML and is currently being evaluated in clinical trials for other hematological 
malignancies and several solid tumors.  Two other notable SFK inhibitors are saracatinib 
(AZD0530, Figure 1.3B) and ponatinib (AP24534, Figure 1.3C).  These inhibitors, while still 
having some level of promiscuity, are reported to be more specific for the SFKs and Abl than 
dasatinib (65,66). 
 Although there have not been many studies exploring SFK inhibition in the context of 
DLBCL, there are some preliminary studies that demonstrate the potential utility of targeting the 
SFKs in this disease.  Ke et al. demonstrated that dasatinib is capable of inhibiting the growth of 
B-cell lymphomas both in vitro and in vivo (37).  Moreover, Davis et al. demonstrated that 
dasatinib is capable of killing cell lines that are dependent on chronic BCR signaling, but has 
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little effect on GCB DLBCL cell lines (9).  In another study, Yang et al. demonstrated that 
dasatinib is capable of inhibiting cell proliferation in some DLBCL cell lines, but not others, and 
that activity of Syk and PLCγ2 correlated with dasatinib sensitivity (38). 
 
1.5 Measuring Kinase Activity – A Global Challenge 
1.5.1 Introduction 
Kinases and the proteins that they phosphorylate constitute the virtual “wiring diagram” 
of the cell.  Collectively, the kinases or kinome dictate key aspects of cell function in normal and 
disease states (67,68).  Understanding the connections and relationships between these cellular 
components is a major objective of current phosphorylation research.  Kinase networks are 
beginning to emerge and the dynamic nature of the kinome is now readily accepted (69-
71).  Ultimately, a more complete kinase network map, and better knowledge of the events 
regulated by kinases, will improve the design and application of targeted kinase inhibitor 
strategies for the treatment of disease.  Essential to this goal is the ability to measure changes in 
kinase activity, either as isolated enzymes or as part of the greater kinome (72).  The objective of 
this section is to discuss some recent advances in these methods and to evaluate their 
applications, advantages, and disadvantages (Figure 1.4).  
Since the original studies of Casnellie and Krebs (73,74), methods to quantitatively 
measure kinase activity remain in demand and have continued to evolve to meet current needs 
(75,76).  Significant progress has been made in the development of methods to measure kinase 
activity in live cells and in a high-throughput, kinome-wide manner.  These developments have 
been fueled by advances in peptide chemistry, fluorescent methodologies, mass spectrometry, 
and other technologies (77-79).  Much of this emphasis is motivated by a need to evaluate kinase 
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inhibitor potency and specificity against the kinome.  This need has been met with both 
commercial and academic developments, some of which will be discussed herein (Table 1.2). 
1.5.2 Early Methods 
The majority of the early methods relied on the use of radioactivity and incorporation of 
32P into proteins or peptide substrates (73,74).  Later, some of these methods shifted to the use of 
33P because of the desirable properties of this isotope, particularly for array-based assays 
(80).  Advantages of array-based assays included increased rapidity, versatility, and the 
quantitative nature of these assays.  Disadvantages included the burdensome maintenance and 
disposal of radioactive waste, as well being limited to purified kinases and/or substrates.  The 
principle of these assays was based on selective binding of the phosphorylated substrate to paper 
or other matrices.  Commonly employed methods used acid precipitation of protein substrates 
(casein, myelin basic protein, histones) followed by extensive TCA washes to remove free 
ATP.  To account for kinase autophosphorylation, substrate negative controls were absolutely 
necessary.  Additionally, substrate peptide binding to phosphocellulose (P-81) paper was 
dependent on basic charge and required sufficient basic residues to allow binding in the presence 
of phosphoric acid (74).  One of the advantages of this approach is that peptide substrates can be 
engineered based on known kinase specificity to optimize the measurement of kinase activity 
either from lysates or enriched samples (81-83). Either approach can be successfully applied to 
quantitatively measure kinase activity.  However, a disadvantage of these methods is that they 
are not suitable for measuring the kinase activity of a large number of kinases at the same time. 
 More recently, these methods have been optimized for high-throughput applications with 
the general goal of testing for inhibitor specificity (84).  One technology of note is the HotSpotSM 
methodology that utilizes miniaturized platforms and purified kinases (578) for inhibitor 
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screening (Reaction Biology Corporation).  Thus, these and other similar assays remain versatile 
approaches to study kinase activity and inhibitor specificity. 
1.5.3 The Emergence of Fluorescent and Luminescent Methods 
Because of the negative implications of the use of radioactivity, non-radioactive methods 
for measuring kinase activity have become increasingly popular.  Many of these methods are 
based on the measurement of fluorescent peptide substrates and take advantage of altered 
fluorescent properties upon phosphorylation (85).  Furthermore, some of these fluorescent- and 
luminescent-based methods are amenable to studies in cell lysates and live cells, providing a 
more natural environment for studying kinase activity.  A very large variety of these in vitro 
kinase assays are now available; for an excellent resource the reader is referred to the review of 
Jia et al. (86).  In general, the fluorescent and luminescent peptide-based kinase assays can be 
broken down into multi-component sensors and unimolecular sensors.  Some of these methods 
are briefly described below. 
1.5.3.1 Multi-component Fluorescent and Luminescent Methods 
The multi-component fluorescent and luminescent methods for measuring kinase activity 
include both direct and indirect measurements of kinase activity.  The more direct measurements 
generally involve a fluorescently-labeled peptide substrate specific for the kinase of interest and 
a secondary component whose binding alters the fluorescence of the peptide substrate.  The more 
indirect measurements utilize enzyme-coupled assays to measure the depletion of ATP or 
production of ADP after the kinase reaction.  The multi-component techniques are best used with 





The majority of the multi-component sensors for kinase activity depend on binding of a 
phosphorylated peptide substrate by a phospho-specific antibody (Figure 1.5A).  Commonly used 
assays, like HTRF (homogeneous time resolved fluorescence) or LANCE (lanthanide chelate 
excitation), measure the generation of a fluorescence resonance energy transfer (FRET) signal 
induced by substrate phosphorylation (87-89).  In these assays, the peptide substrate is labeled 
with a FRET acceptor molecule, generally via streptavidin-biotin binding.  Upon substrate 
phosphorylation, a phospho-specific antibody labeled with a donor molecule can bind, thus 
bringing the donor and acceptor molecules close enough to generate the FRET signal.  The 
AlphaScreen (amplified luminescent proximity homogeneous assay) utilizes a similar bead-
based setup, but produces a luminescence signal rather than fluorescence (90,91).  Advantages of 
these assays include high sensitivity and applicability to high-throughput formats.  Limitations 
include the reliance on europium- or other conjugated phospho-specific antibodies, which can be 
costly.  Furthermore, there may be limitations to which substrates have a corresponding 
phospho-specific antibody. 
1.5.3.1.b Fluorescence Polarization (FP) and Time-Resolved FP 
While fluorescence polarization (FP) techniques also utilize a phospho-specific antibody, 
they are based on a well-established principle of fluorescence anisotropy, rather than FRET (92). 
 When polarized light excites the fluorophore of a fluorescently-labeled peptide, the excited 
fluorophore can rotate rapidly, and therefore emits light in many planes (depolarized light). 
 However, when the fluorescently-labeled peptide is phosphorylated and bound to phospho-
specific antibodies (93) or metal complexes (94), the excited fluorophore rotates more slowly, 
thereby emitting more polarized light.  FP techniques measure the ratio of fluorescence emissions 
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in different planes in order to determine the level of polarization, which is indicative of substrate 
phosphorylation.  These techniques are amenable to high-throughput screening, but they are 
subject to potential compound interference and require a large amount of phosphorylated 
substrate to effectively determine FP.  However, the application of time-resolved anisotropy 
measurements can be used to improve the quality of information obtained from these assays. 
1.5.3.1.c Metal Ion Coordinated Fluorescence Quench Assays 
While the phospho-specific antibody-based assays can provide sensitivity and the 
potential for high-throughput studies, the need for specific antibodies can be costly and limit the 
kinases/substrates that can be studied.  Metal ion coordinated fluorescence quench assays are a 
form of multi-component kinase activity sensors that do not depend on a phospho-specific 
antibody.  Instead of measuring an increase in fluorescence, these assays use a decrease in 
fluorescence as the measure of substrate phosphorylation (95,96).  In these assays, the 
phosphorylation site of a fluorescently-labeled peptide substrate coordinates with a metal 
ion.  The metal ion is associated with a quencher molecule, thus bringing the quencher in close 
enough proximity to absorb the fluorescence of the peptide’s fluorophore, and causing a decrease 
in fluorescence.  A major advantage of these assays is the lack of a phospho-specific antibody, 
thus making them more cost-effective and easily applicable to a variety of 
kinases/substrates.  Some disadvantages are that the reagents used may be sensitive to excessive 
levels of ATP or the chelation agents often used to halt a kinase assay, such as EDTA. 
1.5.3.1.d Enzyme-Coupled Assays 
Enzyme-coupled assays are more versatile than peptide-based substrate assays, as they 
depend solely on the amount of ATP or ADP present after the kinase reaction and do not require 
a synthetic peptide substrate tailored to a given assay and kinase of interest.   The ATP-
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dependent assays measure ATP depletion via luminescence, in which the remaining ATP is used 
to catalyze a luciferase reaction (97).  Thus, luminescence is inversely related to kinase activity.  
The ADP-dependent assays measure ADP accumulation via fluorescent or colorimetric signals, 
in which a pyruvate kinase and lactate dehydrogenase system uses accumulated ADP and NADH 
oxidation to convert phosphoenolpyruvate to lactic acid (98).  In these assays, the readout is 
dependent on NADH concentration, therefore fluorescence/absorbance is inversely related to 
kinase activity.  Since the enzyme-coupled assays generally require cessation of the kinase 
reaction prior to ATP/ADP measurement, another limitation of these assays is that they are 
fixed-timepoint assays, rather than real-time.  However, some work has been done to adapt these 
assays to a kinetic readout (99).  Despite these adaptations, the main disadvantage of the 
enzyme-coupled assays is that they are indirect measurements of kinase activity and require 
purified protein and substrate in order to reduce interference.  Furthermore, if the kinase assays 
are being used to investigate the effects of a compound, the coupled assays may be subject to off-
target interference by the compound. 
1.5.3.2 Unimolecular Fluorescent Methods 
While multi-component assay technologies have proven to be extremely useful, a major 
drawback is the need for multiple components, which requires additional optimization and limits 
the utility of these assays in more physiologically relevant systems, such as cell lysates and 
living cells.  The development of unimolecular fluorescent-based methods for measuring kinase 
activity allows for a more straightforward measurement of kinase activity in cell lysates and 
living cells. 
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1.5.3.2.a Genetically -Encoded FRET Sensors 
Genetically-encoded sensors for kinase activity are generally FRET-based, following the 
original design by Roger Tsien’s group (100,101).  These single-chain constructs consist of a 
kinase substrate sequence (tailored to the kinase of interest), a corresponding phospho-amino 
acid binding domain, a FRET pair of autofluorescent proteins, and flexible linkers where needed 
(Figure 1.5B).  The FRET proteins are located on opposite ends of the construct, so they will not 
interact when the kinase substrate sequence is unphosphorylated.  Once the substrate sequence is 
phosphorylated, the phospho-amino acid binding domain binds the phospho-substrate, thus 
bringing the FRET pair into close proximity and producing a FRET signal.  The major advantage 
of this technique is that it can be used in live cells, thus allowing the study of kinase activity in 
its native environment.  Furthermore, targeting sequences can be implemented to study kinase 
activity in specific cellular compartments (102-104).  Some of the drawbacks of this technique 
are low sensitivity and being genetically-encoded, which means a lack of temporal control and 
control over the level of expression. 
1.5.3.2.b Environmentally-Sensitive Fluorophores 
To avoid the complications of a genetically-encoded construct, environmentally-sensitive 
peptide sensors are a useful alternative.  These sensors consist of a kinase substrate sequence 
labeled with an environmentally-sensitive fluorophore located close to the phosphorylation site 
(Figure 1.5C).  Phosphorylation of the peptide substrate creates a change in the charge near the 
fluorophore, inducing a change in fluorescence intensity or wavelength of the fluorophore 
(57,105-107).  Similarly, chelation-sensitive fluorophores can coordinate with a metal ion in 
response to phosphorylation of a nearby site on a peptide substrate, resulting in a change in 
fluorescence (106,108).  The benefits of environmentally-sensitive sensors are that they can be 
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synthetically produced, avoiding the complications of recombinant systems, and they can 
provide more temporal control and dynamic range than the genetically-encoded sensors. 
 Furthermore, these sensors can be made light-activatable, thereby providing precise temporal 
control (109).  They can be used in whole cells using microinjection, but are more easily applied 
to cell lysates.  The major disadvantage of this technique is that the environmentally-sensitive 
fluorophore must be in close proximity to the phosphorylation site of the peptide substrate, 
which has the potential for interference with kinase binding and phosphorylation.  In addition, 
the need for microinjection when studying kinase activity in live cells requires special equipment 
and training. 
1.5.3.2.c Electrophoretic Mobility Shift Assays 
The electrophoretic mobility shift assays are perhaps the simplest form of unimolecular 
sensors of kinase activity.  They utilize a fluorescently-labeled peptide substrate, in which the 
fluorophore is always fluorescent regardless of phosphorylation status of the peptide 
substrate.  The addition of a phosphate group to the peptide alters its charge and mass, so the 
phospho-peptide will migrate differently from the unphosphorylated peptide in an electric field 
(Figure 1.5D).  Thus, total amounts of phosphorylated and unphosphorylated peptide can be 
determined at various timepoints throughout a kinase reaction.  Examples of electrophoretic 
mobility shift assays include standard CE-LIF (capillary electrophoresis with laser-induced 
fluorescence) approaches (110) and the Caliper Life Sciences LabChip technology, which is a 
miniaturized high-throughput version of CE-LIF (111).  The electrophoretic mobility shift assays 
avoid the need to position the fluorophore in close proximity to the phosphorylation site, and 
provide a very sensitive detection method with the potential for multiplexed analyses.  The CE-
LIF sensors can be adapted for use in living cells through the use of genetically-encoded 
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constructs (112), microinjection (113), or cell-penetrating peptides (114), but they are more 
easily applicable to cell lysates.  A disadvantage of the electrophoretic mobility shift assays is 
that they are fixed-timepoint assays rather than real-time assays.  The use of electrophoresis also 
requires specialized instruments and more time and data analysis than some of the sensors with 
phosphorylation-dependent fluorescence changes. 
1.5.4 Kinome-Wide Methods 
The realization that the kinome is an integrated network of kinases has spurred the 
development of methods to measure changes in the kinome “en masse”.  The majority of the 
focus has been on the human kinome, which is composed of approximately 500 unique members, 
including the less well-characterized pseudokinases (115). A number of different approaches 
have recently been developed and the pros and cons of these methods are discussed below. 
1.5.4.1 RPPA and Phosphoprotein Arrays 
Multiple commercial products and services are available for the large-scale profiling of 
the kinome or their substrates based on protein phosphorylation.  These include antibody arrays 
for measuring changes in receptor and non-receptor kinase activity, serine/threonine kinases, and 
their substrates.  Popular among these is the reverse phase protein array (RPPA) technology for 
profiling phosphoproteins, in which many cell lysate samples are “printed” on a nitrocellulose 
membrane and probed with an antibody of interest (116,117).  Some of the advantages of the 
antibody array methods include high sensitivity, speed, and the lack of need for expensive 
equipment, such as mass spectrometers. 
A number of commercial vendors offer services and reagents for phosphoprotein array 
assays, including R&D Systems, RayBiotech, Kinexus, Full Moon Bio, Cell Signaling 
(PTMScan) and others.  Kinexus has developed bioinformatics analyses to complement their 
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discovery-based assays for kinases and kinase substrates (118).  DiscoverX also offers a variety 
of kinase assay and profiling methods including those for measuring receptor kinase activity 
(PathHunter) and kinase inhibitor specificity assays (KinomeScan) (119). 
 The advantages of these array-based approaches are the rapidity and simplicity of 
analysis.  Both total protein and phosphoprotein detection can be quantified in a specific and 
sensitive manner.  Disadvantages pertain to potential artifacts when measuring total 
phosphorylation changes, such as those obtained with anti-phosphotyrosine arrays.  In this case, 
both positive and negative regulatory sites may be simultaneously detected. 
1.5.4.2 KinoBeads 
Originally developed by Cellzome scientists, based on the work of Daub and others 
(120), the KinoBeads technology has proven to be a powerful approach to study the kinome 
(121,122).  Based on the concept of kinase capture by kinase inhibitors immobilized on 
Sepharose beads, the inclusion of multiple pan kinase inhibitors of differential specificity and 
affinity allows the capture of a large percentage of the kinome in a single experiment.  The 
captured kinases can then be eluted and identified via mass spectrometry or Western blotting.  
Derivatization of kinase inhibitors to include reactive amines or other groups facilitates the rapid 
coupling of these inhibitors to modified Sepharose (ECH) or other supports, and many of these 
derivatized inhibitors are now commercially available.  Thus, inhibitor bead composition can be 
tailored to meet the needs of a particular experiment.  
 Numerous studies have explored the utility of the KinoBead approach to examine the 
kinome.  Initially, the vast majority of the studies were used to profile kinase inhibitor 
specificity, as discussed in these reviews (69,123,124).  Other studies used the KinoBead 
approach to profile changes in the baseline kinome of different cancer cell lines and other cells 
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(121,125,126).  In some instances, this has been effectively combined with phosphoproteomics 
(127,128) and used to investigate changes in the kinome during the cell cycle (129). However, no 
claims were made regarding the ability of these reagents to measure the actual activation state of 
individual kinases in the kinome.  A comparison of kinase capture by KinoBeads to ATP and 
ADP probe-based methods (Desthiobiotin, described below) has been made.  Interestingly, a 
high degree of complementarity between these two methods was observed in these studies (130). 
Further development led to the emergence of commercial ventures like Ambit/DiscoverX, which 
provides large-scale inhibitor specificity screening services.  This remains a popular and 
powerful approach to investigate inhibitor specificity in a “kinome-wide” manner. 
1.5.4.3 Multiplexed Inhibitor Beads 
The Multiplexed Inhibitor Beads (MIBs) approach is an adaptation of the original 
KinoBead technology.  In short, this method uses individual, layered immobilized kinase 
inhibitors in a column-based approach (70) (Figure 1.6).   The philosophy behind layering the 
MIBs was that more abundant kinases could be absorbed onto more highly selective inhibitors 
(top layers), thereby providing additional binding “space” for lower abundance kinases.  The 
original composition of MIBs included the following immobilized inhibitors layered from top to 
bottom: Bisindoylmaleimide-X, SB203580, Lapatinib, Dasatinib, Purvalanol B, VI16832, and 
PP58.  More recent adaptations of this method have included additional inhibitors (131) in an 
effort to extend the coverage of the kinome.  The advantages and disadvantages of these 
alterations are discussed below. 
Combined with quantitative methods of mass spectrometry (MS), MIB/MS was used to 
measure changes in the kinome in response to targeted kinase inhibitors and acquired drug 
resistance (70,132-136).  Based on changes in MIB kinase binding in response to EGF and 
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pervanadate, the ability of MIB/MS to measure changes in the activity of individual kinases was 
reported.  Similarly, kinome changes associated with acquired resistance to imatinib in a model 
of chronic myeloid leukemia was determined.  In both studies, kinases were detected that showed 
dependence on the phosphorylation and activation state of the kinase (70,132).  While the 
number of kinases that displayed activity-dependent binding was limited, these were verified 
with phosphoantibodies and other methods.  This was particularly evident for some members of 
the MAPK and IKK pathways (132).  Thus, the property of inhibitor beads to capture kinases in 
an activity-dependent manner is based on the potential structural changes that result in altered 
affinity of the kinase for an immobilized type 1 inhibitor. 
The ability of MIB/MS to measure kinase activity changes was recently challenged 
(137).  This study compared the ability of similar inhibitor bead mixtures to capture kinases in an 
activity-dependent manner.  Based on their data, the authors concluded that these beads were not 
capturing active kinases preferentially to inactive ones.  Instead, they report that changes in 
kinase abundance were responsible for the difference in kinase capture and quantification. 
While the majority of kinases probably do not show activity-dependent binding with 
published inhibitor bead combinations, there is a fraction that appear to, but this may depend on 
the specific properties of the immobilized inhibitor and the assay conditions.  Unpublished 
studies from the Graves lab at UNC support this premise.  As shown in Figure 1.7, the capture of 
EGF-activated EGFR depends heavily on the inhibitor bead composition.  Of four individual 
inhibitor beads that captured EGFR, three (PP58, Purvalanol B, and Shokat Inhibitor) show 
increased capture of EGFR by several-fold upon EGF stimulation.  The fourth immobilized 
inhibitor, CTx-0294885, shows no increase in EGFR capture. Moreover, inclusion of CTx-
0294885 in a mixture of six inhibitor beads is sufficient to suppress any observed increase in 
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EGFR binding.  Comparison of activity dependent binding of other kinases within the 
EGFR/MAPK signaling pathway shows similar dependency on inhibitor bead composition.  
Thus, the activation state of a kinase may strongly influence or have no detectable effect on 
MIBs binding depending on the composition of the immobilized inhibitors used.  This premise 
was supported by the recent study of Urisman et al. (131), where kinase capture was compared to 
the phosphorylation status of the given kinase.  From these studies, the authors conclude that 
there is an element of activity-dependent binding to inhibitor beads. 
In summary, the strength of this approach is its ability to capture and quantify hundreds 
of kinases in a single experiment, including members of the understudied kinome (138).  
Interestingly, MIB/MS was recently used to profile kinome changes in response to viral infection 
(139) and to examine the kinome of Chlamydomonas (140), demonstrating the versatility of this 
approach.  Combined with analysis of kinase phosphorylation (either by mass spectrometry or 
immunological methods), this technique provides extensive insight into properties of the 
“functional” kinome of a given cell type or tumor.  Thus, it appears that the utility of this method 
to investigate global changes in the kinome remains high. 
1.5.4.4 DigiWest 
Recent advances have extended the application of kinase capture on immobilized kinase 
inhibitors, with the power of Luminex immunodetection.  The DigiWest technology is a 
multistep process that begins with running samples on an SDS-PAGE gel and transferring to a 
nitrocellulose membrane (141).  The separated, membrane-bound proteins are then biotinylated, 
and each lane of the membrane is cut into 96 strips that cover a wide range of molecular weights.  
The proteins are then eluted from the strips and labeled with Neutravidin-coated Luminex beads 
with distinct color-codes for each molecular weight.  The bead-labeled protein samples from a 
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given lane can then be combined, aliquots can be used to probe with hundreds of different 
antibodies, and samples are analyzed using flow cytometry, wherein the signals represent the 
different molecular weights of the initial SDS-PAGE lane.  To use the DigiWest technology to 
the study of the kinome, high-affinity kinase capture beads, such as KinoBeads, are applied to 
the cell lysates prior to the initial SDS-PAGE.  The application is simple in concept and could 
provide a rapid and sensitive new approach to study the kinome in depth.  The authors 
demonstrate the application of this approach to detect low levels of kinase from small amounts of 
tissue material (141).  This may be a particularly useful approach when sample amounts are 
limiting, such as clinical biopsies or laser capture microdissection. 
1.5.4.5 ATP Probes 
1.5.4.5.a Desthiobiotin ATP 
An alternative approach to the inhibitor-based capture methodology described above is 
the application of affinity-based tagging of kinases, as described by Patricelli and co-authors 
(142,143).  This elegant technology takes advantage of reactivity with conserved lysine residues 
found in the majority of protein kinase ATP-binding pockets.  Desthiobiotin ATP reacts with 
these lysines, resulting in a biotin-tagged kinase.  The biotinylated kinase peptides are purified 
by streptavidin affinity chromatography and analyzed by mass spectrometry.  Applying 
principles of Multiple Reaction Monitoring (MRM) or Parallel Reaction Monitoring (PRM) MS, 
these peptides can be rapidly identified and quantified (144).  The tremendous advantage of this 
approach is that the binding of desthiobiotin ATP shows preference for the “activated” kinase, 
and thereby provides a covalent probe to tag only active kinases.  The technology has been 
commercialized and is available either as a service (KiNativ) or as a kit-based format (145). 
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1.5.4.5.b Shokat Approach 
A well-accepted approach to study kinase specificity was developed by Kevan Shokat 
(146).  Based on the application of modified ATP analogs and kinases mutated to accept only the 
modified ATP molecules, the authors demonstrated that this approach can be used to identify 
direct substrate targets for desired kinases.  Known as the analog-sensitive (AS) approach, this 
methodology has shown great application to identify novel substrates for kinases like PKA, SRC, 
CDK2, EPHA4, and many more.   In fact, this approach has been successfully applied to the 
study of over 80 kinases (for an excellent review see (147)).  In addition to providing insight into 
global analysis of kinase substrates in yeast, mammalian cells, and multicellular organisms, this 
approach has also contributed significantly to kinase inhibitor design. 
1.5.4.5.c Other Covalent Approaches 
The recent study of Zhao and co-authors (148) describe the design of cell-permeable, 
lysine-directed kinase inhibitor probes.   These molecules are based on sulfonyl fluoride 
reactivity and provide a method to “tag” kinases in live cells, under physiological ATP 
concentrations and conditions.  Using these probes to test dasatinib potency, the authors show a 
greater selectivity of dasatinib than would have been predicted based on conventional kinase 
inhibitor screens.  The development of chemically reactive kinase probes offers significant 
potential for a better understanding of kinase targets. 
1.5.5 Assessing Kinase Interactors and Substrates by Biotinylation: BioID Approach 
The BioID (proximity-dependent biotin identification) technique relies on the fusion of 
the kinase being studied to a mutated, promiscuous form of BirA, a biotin ligase from 
Escherichia coli (149).  The BirA gene used for BioID has a point mutation that results in a 
ligase (BirA-R118G (BirA*)) with decreased affinity for biotinyl-5’-AMP, the highly reactive 
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intermediate of the biotinylation reaction (150).  When a BirA*-kinase fusion protein is 
expressed in cells grown in media supplemented with biotin, the biotinyl-5’-AMP molecule is 
released by BirA* and irreversibly biotinylates lysine residues on proximal proteins (within ~10 
nm), with no required biotinylation consensus sequence (151,152) (Figure 1.8).  Biotinylated 
proteins can then be captured with streptavidin Sepharose and identified by mass spectrometry, 
to ultimately identify proximal proteins and candidate kinase substrates.  Comprehensive 
protocols are available as guides for implementation of the BioID technique (149,152-154). 
 When using the BioID technique, careful consideration must be taken to ensure that the 
fusion of BirA* to the kinase of interest does not affect subcellular localization.  A potential 
alternative is a smaller biotin ligase from Aquifex aeolicus (designated BioID2), which is less 
likely to affect normal subcellular localization of fusion proteins than the original BioID 
construct, and thus may be useful for kinases with N- or C-terminal localization domains 
(155).  However, the BirA* used in BioID2 is also capable of catalyzing the biotinylation of 
proteins using much lower concentrations of biotin than the original BioID construct.  BioID2 is 
therefore unsuitable for any time-sensitive experiments, such as those involving cell cycle 
synchronization or drug treatment (155).    
The BioID technique has been used previously to identify novel interactors of the kinase 
EphA2 and a novel substrate of Plk4 (156,157).  It is important to note that, using BioID, 
complementary approaches must be used to determine whether interactors are bona fide 
substrates, or merely proteins in close proximity.  This technique has also been used to validate 
the physiological relevance of kinase interactions that were identified by other means 
(158,159).  Extensive reviews emphasizing the capabilities and limitations of the BioID approach 
have been published recently (160,161). 
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1.5.6 Future Directions 
The power of assaying the kinome “en masse” is just beginning to be realized.  Emerging 
areas include applying these approaches to study host-viral interactions and the impact of 
parasitic infections, the development of brain pathologies like Alzheimer’s disease, probing 
stromal/tumor cell interactions, illuminating the basis of rare diseases (including those driven by 
kinase fusions or mutations), determining kinome-wide specificity of uncharacterized kinase 
inhibitors, and elucidating kinome adaptions to loss of key proteins like Ras and p53.  
Ultimately, these studies are expected to define the unique kinome “fingerprints” that arise from 
these perturbations, with the hope that novel therapeutic targets can be identified.  For example, 
the recent study of Arend et al. (139) applied this approach to identify kinase adaptations in 
response to human cytomegalovirus (HCMV) infection.  Using this information, existing kinase 
inhibitors were selected and effectively demonstrated to have anti-viral activity (139). 
 Future applications include combining these technologies with targeted mass 
spectrometry approaches, such as multiple reaction or parallel reaction monitoring (MRM/PRM).  
This approach has the value of greatly improved sensitivity and reproducibility, making it an 
attractive option for rare or low-abundance clinical samples.  The study of Miao and co-authors 
(162) demonstrated the quantification of 328 kinases by MRM and measured their response to 
methylgloxal stimulation.  Recently, MIB kinome capture was successfully combined with PRM 
mass spectrometry (131).  These studies investigated the adaptive responses to MEK and Erk 
inhibitors in colorectal cancer cells.  In addition to quantifying over 800 peptides from 150 
kinases, these authors demonstrated a compensatory activation of the TGF-beta family receptors 
to these inhibitors.  Thus, these types of technical adaptions have the potential to greatly extend 
the application of kinome analysis to important clinical problems. 
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1.5.7 Conclusion/Discussion 
The need to quantitatively and specifically measure kinase activity across the kinome 
remains important for many areas of biology.  With the emergence of global methods to measure 
RNA and DNA, it is even more important to be able to measure proteins and their 
substrates.  This is particularly relevant given the low degree of correlation between protein and 
RNA expression.  Kinases, as a class of enzymes, are one of the most diverse groups of enzymes 
because of the multitude of events that they control.  A deeper understanding of how this 
important network is regulated will contribute extensively to our comprehension of cell 
signaling. 
 
1.6 The Proteasome 
The ubiquitin-proteasome system is critical for the quality control of most, if not all, 
proteins within a cell.  It serves as the primary proteolytic system for the degradation of 
misfolded or damaged proteins and proteins targeted for downregulation.  As part of the 
ubiquitin-proteasome pathway, proteins destined for degradation are labeled with polyubiquitin 
chains, which can then be recognized and bound by the proteasome.  The proteasome then 
unfolds these proteins in an ATP-dependent manner and trypsinizes them (163). 
The proteasome is a multi-subunit protein, with its proteolytic activity being derived from 
the 20S core particle.  The 20S core particle is a barrel-shaped structure comprised of two 
heteroheptameric outer α-rings and two heteroheptameric inner β-rings (164) (Table 1.3, Figure 
1.9).  The core particle has three distinct proteolytic activities: caspase-like (CaL), trypsin-like 
(TL), and chymotrypsin-like (ChL), which are provided by its β1, β2, and β5 subunits, 
respectively (163).  In immune cells, or in nonimmune cells in the presence of interferon or 
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tumor necrosis factor, each of these subunits can be replaced by immunoproteasome subunits 
β1i, β2i, and β5i, respectively, resulting in either mixed proteasomes, with one or two subunits 
replaced, or the full immunoproteasome when all three are substituted (163,165).  This produces 
a proteasome with altered cleavage patterns favoring the production of peptides involved in 
antigen presentation (163,166,167). 
Although the 20S core particle has proteolytic activity, it is generally unable to degrade 
folded proteins without a regulatory particle cap, as the N-terminal tails of some of the α subunits 
form a gate at the entrance to the 20S core particle (168,169).  Binding of a regulatory particle to 
the 20S core particle induces a conformational change that displaces the α subunit tails and opens 
the gate to the 20S core particle (170).  In addition to opening the gate, the regulatory particles 
serve as a lid to the 20S core particle and facilitate binding, unfolding, and entry of proteasome 
substrates.  There are four different regulatory particles that can bind to the 20S core particle: 
PA700 (also known as 19S), PA28αβ, PA28γ, and PA200 (163).  Considering the variety of 
regulatory particles and catalytic 20S subunits, there is potential for several forms of the 
proteasome to exist within a given tissue, or even within an individual cell (171,172).  However, 
the most well-studied and predominant form of the proteasome is the 26S proteasome, which 
includes the 20S core particle and one or two 19S regulatory particle(s) (Table 1.3, Figure 1.9). 
 
1.7 Role of the Proteasome in Cancer and Lymphoma 
The function of the proteasome within the cell can be likened to that of a garbage 
disposal.  As a garbage disposal chops up and disposes of unwanted food, the proteasome is 
responsible for degrading proteins that are damaged or no longer needed (173).    It plays a role 
in a number of signaling pathways, including cell cycle regulation (174), transcription (175), and 
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signal transduction (176).  The proteasome is therefore critical for maintaining the health and 
viability of a cell.  As such, it is not surprising that aberrant proteasome activity is linked with 
disease.  For example, proteasome activity is often upregulated in cancer (172,177,178), but 
downregulated in neurodegenerative diseases (179).  Consequently, there has been and continues 
to be a high level of interest in the proteasome as a therapeutic target. 
In addition to the SFKs, the proteasome has also been implicated in cancer and drug 
resistance due to its degradation of various antitumor-related proteins (180,181).  Notable 
proteins regulated by the proteasome include IκB, the tumor suppressor p53, the cyclin-
dependent kinase (CDK) inhibitors p21 and p27, and members of the MAPK pathway (180).  As 
noted earlier, the ABC subtype of DLBCL is heavily dependent on chronic BCR and NF-κB 
signaling (9,10).  The anti-apoptotic NF-κB signaling pathway is heavily dependent upon the 
proteasome because negative regulator of NF-κB, IκB, is degraded by the proteasome in 
response to phosphorylation by IκB kinase (IKK).  Thus, there is potential use for proteasome 
inhibitors in the treatment of ABC DLBCL. 
There are currently three FDA-approved proteasome inhibitors: bortezomib (PS-341 or 
Velcade, Figure 1.10A), carfilzomib (PR-171 or Kyprolis, Figure 1.10B), and ixazomib (MLN-
2238 or Ninlaro, Figure 1.10C) (182).  These inhibitors preferentially target the β5 subunit of the 
proteasome, which confers the proteasome’s ChL activity (183-186).  Bortezomib and ixazomib 
are slowly reversible inhibitors, whereas carfilzomib is an irreversible proteasome inhibitor 
(186,187).  All three inhibitors are indicated for the treatment of multiple myeloma, a cancer of 
plasma B-cells, and are currently in clinical trials for other hematological and solid malignancies.  
In fact, both bortezomib and carfilzomib are currently in clinical trials for the treatment of 
DLBCL.  Several preclinical studies have demonstrated cytotoxic and/or antitumor activities of 
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proteasome inhibitors in various hematological malignancies (11,188,189).  Furthermore, there is 
evidence that when combined with standard chemotherapy, bortezomib has a significant effect 
on ABC DLBCL but not on GCB DLBCL patients (12,190). 
Interestingly, several studies have demonstrated synergy between proteasome inhibitors 
and many other agents, including tyrosine kinase inhibitors, particularly within hematological 
cells (191-195).  The Btk inhibitor ibrutinib (PCI-32765) has garnered interest for the treatment 
of DLBCL (34), and Dasmahapatra et al. have shown that ibrutinib and bortezomib 
demonstrated synergy in DLBCL and mantle cell lymphoma cells (194).  The combination of 
ibrutinib with proteasome inhibitors and standard chemotherapy (R-CHOP) is currently under 
investigation in a Phase I/II clinical trial.  Considering the proximity of Btk activation to SFK 
activation in BCR signaling, it stands to reason that SFK inhibitors, such as dasatinib, may prove 
to be synergistic with proteasome inhibitors in DLBCL. 
 
1.8 Strategies for Measuring Proteasome Activity 
The 20S core particle of the proteasome has three proteolytic activities, caspase-like 
(CaL), trypsin-like (TL), and chymotrypsin-like (ChL), which are provided by its β1, β2, and β5 
subunits, respectively (163).  Several methods have been developed to assays these activities 
(Table 1.4). 
1.8.1 Fluorogenic Peptide Substrates 
The most commonly cited method for profiling proteasome activity is the use of peptide 
substrates that are biochemically acted upon by one of the proteasome’s three proteolytic 
activities.  These substrates are fluorescently labeled, but the fluorescence is internally quenched 
in the intact peptide (196).  Upon cleavage by the specific proteasome active site, part of the 
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fluorophore-labeled peptide may dissociate, thus allowing an increase in fluorescence.  
Therefore, changes in fluorescence are directly related to proteasome activity.  The most 
common fluorescent tag used with the fluorogenic peptide substrates is 7-amino-4-
methylcoumarin.  While other fluorescent tags have been used, they tend to have similar 
photophysical properties, which limits the ability to measure multiple proteasome activities 
simultaneously (197-199).  There is a variation of this assay that utilizes a coupled luminescent 
readout instead of fluorescence (200), but it is still subject to the same limitations of the 
fluorescent-based assay. 
1.8.2 Site-specific Activity-based Probes 
Site-specific activity-based probes (ABPs) will target and irreversibly bind to the 
catalytic subunits of the proteasome.  The covalently bound ABS can then be detected using 
antibodies directed against part of the ABP (201) or fluorescent labeling of the probe (202).  
Several of these probes have been described and used to assess the functional proteomics of the 
proteasome (201,203,204).  The advantage of these probes is that they can be made cell-
permeable, thus allowing assessment of proteasome activity in a more native environment 
(196,201).  However, their main disadvantage lies in the nature of suicide substrates, which will 
inactivate an enzyme and may prevent a true readout of enzymatic activity. 
1.8.3 Molecular Imaging 
Molecular imaging is meant to be a non-invasive process that allows the measurement of 
proteasome activity in live cells and potentially in vivo.  The approaches utilizing this technique 
have generally used either exogenously-delivered probes or genetically-encoded probes (196).  
In both cases, the probes can serve as proteasome substrates and will display a change in 
fluorescence or bioluminescence upon proteasomal processing.  Examples of these probes 
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include ubiquitin-firefly luciferase (Ub-FL) and ubiquitin-green fluorescent protein (UbG76V-
GFP) (205,206).  The advantage of the molecular imaging technique is that it allows for a 
measurement of proteasome activity with respect to whole proteins, as opposed to peptide 
substrates.  However, the need to exogenously introduce or genetically encode these constructs is 
not ideal and may perturb cells, or may not even be feasible for some cell types. 
1.8.4 RFDD-PCR and Proteomics 
On a more global level, restriction fragment differential display polymerase chain 
reaction (RFDD-PCR) and proteomics can be used to identify differentially expressed genes and 
study the structure and function of related proteins, respectively (196,207).  This technique 
allows a global comparison of changes in gene expression with changes in protein expression.  
However, it technically is not a direct measure of proteasome activity. 
1.8.5 Immunological Methods 
In addition to traditional western blotting, enzyme-linked immunosorbent assays (ELISA) 
can be used to quantify the 20S core particle of the proteasome (196,208).  Although at its first 
use this technique was limited to purified 20S proteasome, it has since been adapted for use in 
cell extracts and crude lysates as well as for the identification of the 26S proteasome (208,209).  
The advantages of this technique are that the protocols are easy to follow and it can be carried 
out in most laboratories.  However, this assay cannot distinguish between single- or doubly-
capped 26S proteasomes, and measures the amount of proteasome as opposed to its actual 
activity. 
1.8.6 Simultaneous Measurement of All Three Proteasome Catalytic Activities  
Fluorogenic peptide substrates provide the best means for directly measuring the 
proteasome’s three catalytic activities, but are severely limited in the ability to measure more 
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than one activity at a time.  Thus, there is considerable interest in identifying probes that 
discriminate between and simultaneously assess the catalytic subunits of the proteasome (210-
212).  In this regard, our group has previously reported the first example of a set of fluorescent, 
real-time, peptide-based sensors capable of simultaneously monitoring all three of the 
proteasome’s proteolytic activities (Figure 1.11) (213).  Each sensor is comprised of a 
fluorophore, a peptide specific for one of the three proteasome activities, and a quencher.  These 
proteasome sensors possess photochemically distinct fluorophores: fluorescein (λex = 488 nm) 
for the ChL sensor, tetramethylrhodamine (λex = 550 nm) for the TL sensor, and DyLight633 (λex 
= 633 nm) for the CaL sensor, appended to the N-terminus of the recognition sequences selective 
for each proteasomal activity [ChL: Fluorophore-His-His-Ser-Leu-Lys(Quencher); TL: 
Fluorophore-Leu-Arg-Arg-Lys(Quencher); CaL: Fluorophore-norLeu-Pro-norLeu-Asp-
Lys(Quencher)].  A broad-spectrum quencher, an acid blue 40 derivative (AB40) (214), is 
appended to the C-terminal lysine residue on each sensor.  In the intact sensor, the fluorescence 
of the fluorophore is internally quenched by a covalently appended dye (AB40), but upon 
proteolysis of the peptide, the fluorophore dissociates from the quencher and becomes 
fluorescent, furnishing a fluorescent enhancement of 30- to 140-fold for each peptide (213). 
 
1.9 Potential Cross Talk Between the SFKs and the Proteasome 
Although the proteasome and the SFKs each appear to independently play a role in 
promoting a neoplastic phenotype in primarily ABC DLBCL over GCB DLBCL, there is 
evidence for cross talk between these proteins.  Treatment with proteasome or SFK inhibitors 
reduces the growth of lymphoma cells in vitro and in vivo (11,37,38,215,216), indicating that 
both the SFKs and the proteasome could be valuable targets for targeted DLBCL chemotherapy.  
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A recent study by Crawford et al. (192) demonstrated that treatment of chronic myelogenous 
leukemia cells with tyrosine kinase inhibitors and proteasome inhibitors produces a synergistic 
effect.  There is some evidence of cross talk between the SFKs and the proteasome (Figure 1.12), 
but there is much more to learn about the mechanisms connecting these proteins.  The SFKs are 
involved in many signaling pathways that feed into the proteasome, such as NF-κB and 
MAPK/ERK signaling (217-220).  In addition, the SFKs themselves are degraded by the 
proteasome (221,222).  However, direct links between SFK activity and proteasome activation 
are not well understood.  The proteasome can be transcriptionally activated by Jak/STAT 
signaling (223,224).  In C. elegans, EGF signaling through the Ras-MAPK pathways has been 
shown to activate the proteasome (225).  The SFKs can promote both Jak/STAT and EGF 
signaling (226), and may therefore promote proteasome activation.  One study demonstrated that 
treatment with the SFK inhibitor dasatinib led to decreased gene expression of several STAT 
proteins (227).  Thus, there is evidence that the SFK and proteasome pathways are connected. 
 
1.10 Scope of Dissertation 
The following chapters of this dissertation will explore potential chemotherapeutic agents 
for the treatment of DLBCL, notably the SFK inhibitor dasatinib and site-specific inhibitors of 
the proteasome.  Chapter 2 will explore sensitivity to dasatinib and the effects of dasatinib on the 
kinome in a panel of ABC and GCB DLBCL cell lines.  This chapter is in preparation to be 
submitted as a manuscript to the Journal of Proteome Research.  Chapter 3 will explore the 
effects of dasatinib on the proteasome in the same panel of cell lines.  Chapter 4, which is 
submitted as a manuscript to ACS Chemical Biology, will examine the sensitivities of several 
different cancer cell lines to site-specific inhibitors of the β2 and β1 proteasome subunits.  
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Pattern of Expression Isoforms 
Blk B-cells - 
Fgr Myeloid cells, B-cells - 
Fyn Ubiquitous T-cell specific isoform (FynT) 
Frk Primarily epithelial cells - 
Hck Myeloid cells Two different translational starts 
Lck T-cells, NK cells, brain - 
Lyn B-cells, myeloid cells, brain Two alternatively spliced forms 
Src Ubiquitous Two neuron-specific isoforms 
Yes Ubiquitous - 
 
Table 1.1: Src family kinase members 


















Radiometric assays [γ-32P]- or [γ-33P]-labelled ATP Purified protein, cell lysates Endpoint Scintillation counting Yes No 
HTRF/LANCE 
Phospho-specific antibodies and 
FRET 
Purified protein, cell lysates Endpoint Fluorescence plate reader Yes No 
AlphaScreen 
Phospho-specific antibodies and 
luminescence 
Purified protein, cell lysates Endpoint Luminescence plate reader Yes No 
Fluorescence polarization 





Fluorescence plate reader Yes No 
Metal ion coordinated 
fluorescence quench 
Metal ion coordination and 
fluorescence quenching 
Purified protein, cell lysates 
Endpoint or 
kinetic 
Fluorescence plate reader Yes No 








Phospho-substrate binding domains 
and FRET 
Live cells Kinetic Fluorescence microscopy No Yes 
Environmentally-sensitive 
fluorophores 
Charge- or chelation-sensitive 
fluorophores 
Purified protein, cell 
lysates, live cells 
Endpoint or 
kinetic 





Charge alters electrophoretic 
migration 
Purified protein, cell 
lysates, live cells 
Endpoint 
Capillary electrophoresis with 
laser-induced fluorescence 
Somewhat Yes 
RPPA and phosphoprotein 
assays 
Immune detection of known proteins 
and phosphorylation sites 





Kinase capture on immobilized kinase 
inhibitor beads 
Purified protein, cell lysates Endpoint Mass spectrometry No No 
Multiplexed inhibitor beads 
(MIBs) 
Kinase capture on layers of 
immobilized kinase inhibitor beads 
Purified protein, cell lysates Endpoint Mass spectrometry No No 
DigiWest 
Kinase capture on immobilized kinase 
inhibitor beads followed by 
immune detection of known 
proteins and phosphorylation sites 





Covalent modification of active 
kinases 
Purified protein, cell 
lysates, live cells 
Endpoint Mass spectrometry No No 
Shokat approach 
ATP analog assay of kinase 
specificity  
Purified protein, cell 
lysates, live cells 
Endpoint Mass spectrometry No No 
BioID 
In cell biotinylation of neighboring 
proteins 
Live cells Endpoint Mass spectrometry No No 
 
Table 1.2: Summary of technologies for measuring kinase activity 














α1 PSMA6  
α2 PSMA2  
α3 PSMA4  
α4 PSMA7  
α5 PSMA5  
α6 PSMA1  
α7 PSMA3  
β-ring 
β1 PSMB6 Caspase-like proteolysis 
β2 PSMB7 Trypsin-like proteolysis 
β3 PSMB3  
β4 PSMB2  
β5 PSMB5 Chymotrypsin-like proteolysis 
β6 PSMB1  
β7 PSMB4  
β1i PSMB9/LMP2 Caspase-like proteolysis (immunoproteasome) 
β2i PSMB10/LMP10 Trypsin-like proteolysis (immunoproteasome) 
β5i PSMB8/LMP7 Chymotrypsin-like proteolysis (immunoproteasome) 















Rpt1 PSMC2 ATP-dependent protein unfolding; binds to 20S CP α-ring 
Rpt2 PSMC1 ATP-dependent protein unfolding; binds to 20S CP α-ring 
Rpt3 PSMC4 ATP-dependent protein unfolding; binds to 20S CP α-ring 
Rpt4 PSMC6 ATP-dependent protein unfolding; binds to 20S CP α-ring 
Rpt5 PSMC3 ATP-dependent protein unfolding; binds to 20S CP α-ring 
Rpt6 PSMC5 ATP-dependent protein unfolding; binds to 20S CP α-ring 
Rpn1 PSMD2 Ubiquitin receptor (Rpn10) docking 
Rpn2 PSMD1 Ubiquitin receptor (Rpn13) docking 
Rpn13 ADRM1 Ubiquitin receptor/Binding of ubiquitinated proteins 
lid 
Rpn10 PSMD4 Ubiquitin receptor/Binding of ubiquitinated proteins 
Rpn3 PSMD3  
Rpn5 PSMD12  
Rpn6 PSMD11  
Rpn7 PSMD6  
Rpn8 PSMD7  
Rpn9 PSMD13  
Rpn11 PSMD14 Deubiquitinase 
Rpn12 PSMD8  
PA28αβ RP 
PA28α PSME1  
PA28β PSME2  
PA28γ RP PA28γ PSME3  
PA200 RP PA200 PSME4/PA200  
 
Table 1.3: Proteasome subunits and their function 
List of the proteasome’s 20S core particle subunits and various regulatory particle subunits.  
Note: the β1i, β2i, β5i, and β5t 20S core particle subunits are not necessarily expressed in every 
proteasome, but are induced in certain cell types after certain stimuli, such as IFNγ.  CP = core 


























Individual: β1 (CaL), β2 
(TL), or β5 (ChL) 
Activity-based probes 
(ABPs) 
Suicide substrates irreversibly 
bind to proteasome, detected 
via antibodies or fluorescent 
labeling 
Purified or live cells Endpoint 
Fluorescence plate 
reader or fluorescence 
microscopy 
Individual: β1 (CaL), β2 
(TL), or β5 (ChL) 
Molecular imaging 
Degradation of fluorescent or 
luminescent proteins 










Global changes in proteasome 
gene expression 
Extracted RNA Endpoint 
Electrophoresis of PCR 
products 
None (measures amount) 
Proteomics 
Global changes in proteasome 
protein expression 
Cell lysates Endpoint Mass spectrometry None (measures amount) 
Immunological 
methods 
Antibodies detect levels of 
proteasome protein (western 
blotting or ELISA) 





None (measures amount) 
Priestman et al. 
fluorogenic peptide 
substrates (213) 






Simultaneous: β1 (CaL), 
β2 (TL), and β5 (ChL) 
 
Table 1.4: Summary of technologies for measuring proteasome activity 





Figure 1.1: Structure and activation of the Src family kinases 
Schematic representation of SFK domain structure and protein folding.  (A) Comparison of the 
molecular structures of human Src, chicken c-Src, and chicken v-Src.  Each of the SFK members 
have four key Src homology (SH) domains: SH1, the kinase domain; SH2, a phospho-tyrosine 
binding domain; SH3, a domain that binds proline-rich amino acid sequences; and SH4, which 
contains a myristoylation site important for membrane anchoring.  In addition to these domains, 
each SFK member has a C-terminal tail, containing an autoinhibitory tyrosine phosphorylation 
site, and a unique N-terminal region whose function remains unclear.  (B) Inactivation of human 
Src occurs when its C-terminal Tyr530 is phosphorylated and it binds back to the SH2 domain.  
This interaction and an interaction between the SH3 domain and the kinase domain result in a 
closed molecular structure with diminished access of substrates to the kinase domain.  
Conversely, Src activation occurs with removal of the C-terminal phosphotyrosine, displacement 
of inhibitory intramolecular interactions, and opening of the Src molecular structure.  Full 
activation involves phosphorylation at Tyr419. M, myristoylation; P, phosphorylation.  Figure 




Figure 1.2: B-cell receptor signaling 
Signal transduction initiates at the cell membrane following ligand-induced aggregation of the 
membrane immunoglobulin (mIg) and associated signal transducing elements Igα and Igβ.  
Signals are then propagated by means of protein phosphorylation, modification, and interaction.  
The culmination of the signaling cascade is the regulation of transcription factor activation and 





Figure 1.3: Chemical structures of SFK inhibitors 





Figure 1.4: Measuring the kinome 
Graphical representation of the various technologies for measuring kinase activity that are 





Figure 1.5: Schematics of several of the peptide-based sensors for kinase activity 
(A) Example of a multi-component assay that uses a phospho-specific antibody, such as HRTF or 
LANCE.  After phosphorylation of the substrate, binding of a pair of FRET molecules (via 
labeled antibody or biotin-streptavidin) brings the donor and acceptor molecules into close 
enough proximity to generate a FRET signal.  (B) Example of a genetically-encoded 
unimolecular sensor.  Upon phosphorylation, the phospho-substrate binding domain binds to the 
phosphorylated substrate, bringing a pair of FRET proteins in close enough proximity to generate 
a FRET signal.  YFP = yellow fluorescent protein, CFP = cyan fluorescent protein.  (C) Example 
of a peptide sensor with an environmentally-sensitive fluorophore.  Added charge from the 
phosphorylation of the substrate causes a change in the fluorescent properties of the fluorophore.  
(D) Example of an electrophoretic mobility shift assay.  Permanently fluorescent substrates are 
separated into phosphorylated and nonphosphorylated substrates by an electric field and 





Figure 1.6: Graphical representation of MIB/MS 
Control and treated cells are lysed and clarified by centrifugation prior to being passed over a 
column layered with kinase inhibitors immobilized on sepharose beads (MIBs).  Kinases capture 
by MIBs is based on affinity of kinases for the immobilized inhibitors, kinase expression, and the 
activation state of the kinase.  Bound kinases are eluted from the column and trypsinized to 
prepare samples for analysis by mass spectrometry (MS).  Kinases in each sample are identified 
and quantified using quantitative MS and the relative abundance are calculated by isotobaric 
labeling or label free quantification of peptides.  Kinome dynamics are determined by 
quantifying changes in MIB binding of hundreds of kinases simultaneously.  Kinome tree 





Figure 1.7: Inhibitor bead composition defines activity-dependent capture by MIB/MS 
SUM159 cells were serum starved for 24 hours then treated for 15 minutes with 100 ng/mL EGF 
prior to kinase enrichment using multiplexed inhibitor beads (MIB) and label free quantification 
(LFQ) by mass spectrometry (MS).  Short-term agonist treatment minimizes changes in protein 
abundance.  The ratio of EGF stimulated over serum starved control cells are plotted for EGFR 
(left) or the indicated kinases (right).  A value >1 indicates increased capture by MIBs in 
response to EGF stimulation.  Failure to capture or quantify an indicated kinase is denoted with 





Figure 1.8: BioID schematic with BirA*-Kinase fusion protein 
Autobiotinylation of the BirA*-Kinase fusion occurs.  Interacting and proximal proteins that fall 
within the ~10 nm labeling radius (green circle) of BirA* are biotinylated.  Direct interactors are 





Figure 1.9: Structure of the 26S proteasome 
(A) Schematic diagram of structure of and proteolysis by the 26S proteasome.  (B) Schematic 
depicting a flattened subunit structure of the 26S proteasome.  CP = core particle; RP = 
regulatory particle; Rpt = RP triple-ATPase; Rpn = RP non-ATPase.  Figures adapted and 





Figure 1.10: Chemical structures of proteasome inhibitors 
Chemical structures of the proteasome inhibitors (A) bortezomib, (B) carfilzomib, and (C) 
ixazomib.  Bortezomib, carfilzomib, and ixaxomib preferentially target the β5 subunit (ChL 





Figure 1.11: Proteasome activity determination by fluorescent sensors 
(A) Multicolor monitoring of proteasome activity.  ChL, chymotrypsin-like; TL, trypsin-like; 
CaL, caspase-like; AB40, acid blue 40.  (B) Proteasome activities from different fractions of 
HeLa cell lysis procedure.  “ID 26S fraction” indicates samples that were immunodepleted of the 
proteasome.  Figure adapted and reprinted with permission from the publisher (213).  Further 
permissions related to this figure should be directed to the American Chemical Society.  The 





Figure 1.12: Possible mechanisms of cross talk between the SFKs and the proteasome 





CHAPTER 2: DASATINIB IS PREFERENTIALLY ACTIVE IN THE ACTIVATED B-
CELL SUBTYPE OF DIFFUSE LARGE B-CELL LYMPHOMA2 
 
2.1 Introduction 
Non-Hodgkin lymphoma (NHL) is the seventh most common cancer in the United States, 
with diffuse large B-cell lymphoma (DLBCL) being the most common subtype (1-3).  The 
standard treatment of DLBCL is a cocktail of chemotherapeutic agents called R-CHOP, which 
includes rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.  However, 
roughly 10% of DLBCL patients will be refractory (non-responsive) to this therapy, and a 
substantial 40% of DLBCL patients who do respond to R-CHOP will relapse within 5 years (7).  
Although the standard R-CHOP chemotherapy regimen has a relatively high cure rate for 
patients with a good prognosis (2,8), patients with refractory and relapsed DLBCL pose a 
significant challenge to effective treatment.  By gene expression profiling, DLBCL patients can 
be categorized into two clinically relevant subtypes: activated B-cell (ABC) and germinal center 
B-cell (GCB) (4).  Patients with ABC DLBCL generally have a much poorer prognosis than 
those with GCB DLBCL (5,6).  Despite these distinctions, there are currently no established 
treatment differences between these two subtypes.  Although some therapeutic agents have 
shown preferential activity in the poor prognosis ABC subtype (19), none of these agents are 
FDA-approved for use in DLBCL.  Thus, a better understanding of the cellular processes that 
contribute to tumor progression and drug resistance in DLBCL would complement ongoing 
                                                 
2 This chapter is in preparation to be submitted as an article in the Journal of Proteome Research.  The original 
citation is as follows: 
Cann ML, Herring LE, Gilbert TSK, Richards KL, Graves LM, Lawrence DS. Dasatinib is preferentially active in 
the activated B-cell subtype of diffuse large B-cell lymphoma. J Proteome Res. 2017. In preparation. 
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studies of promising therapeutic agents and could lead to the identification of additional 
therapeutic targets for the treatment of relapsed and refractory DLBCL. 
Chronic, overactive signaling through the B-cell receptor (BCR) and the anti-apoptotic 
NF-κB pathway are hallmarks of the ABC but not the GCB DLBCL subtype (9,10), and may be 
particularly important for promoting tumor progression and drug resistance.  Signaling through 
the BCR triggers the activation of many pro-survival and anti-apoptotic signaling pathways, 
including the NF-κB pathway.  Important kinase mediators of BCR signaling are Syk and Btk, 
both of which have inhibitors in clinical trials for the treatment of DLBCL as well as other types 
of lymphoma (58).  The Src family kinases (SFKs) are a family of nine nonreceptor tyrosine 
kinases that facilitate signaling from the BCR to Syk and Btk.  The SFKs also play a role in 
signaling from many other receptors, facilitating several proliferation, survival, and cell motility 
pathways (22,23,29).  Based on SFK involvement in these signaling pathways, it is not surprising 
that the SFKs have been implicated in progression and drug resistance in many cancers, 
including lymphoma (9,29,37,38). 
We hypothesized that SFK inhibitors would provide a viable option for the treatment of 
the ABC subtype of DLBCL.  Dasatinib (Sprycel) is an FDA-approved kinase inhibitor that 
broadly targets SFKs and other kinases, and is used for treatment of leukemia (228).  We 
explored the effects of dasatinib and other SFK inhibitors in a panel of ABC and GCB DLBCL 
cell lines, and found that the ABC DLBCL cell lines are considerably more sensitive to dasatinib 
than the GCB DLBCL cell lines.  However, both subtypes display inhibition of the SFKs in 
response to dasatinib after both short- and long-term treatment, as determined by western blot 
analysis.  The difference in dasatinib sensitivities is due to either differences in signaling 
inhibition downstream of the SFKs or an off-target effect of dasatinib.   We used a kinase 
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enrichment approach, multiplex inhibitor beads coupled to mass spectrometry (MIB/MS) (70), to 
determine the effects of dasatinib on the kinome.  The MIB/MS technique revealed that a large 
number of kinases involved in cell cycle regulation are inhibited in the ABC DLBCL subtype, 
but not in the GCB DLBCL subtype, in response to long-term dasatinib treatment.  Our findings 
highlight the potential use for dasatinib in the treatment of DLBCL. 
 
2.2 Materials and Methods 
2.2.1 Cell Culture 
The Farage cell line was purchased from ATCC, the HBL-1 cell line was obtained from 
Ben Major, the HT, Karpas 422, OCI-Ly3 cell lines were obtained from Steven Park, and the 
OCI-Ly10 and TMD8 cell lines were obtained from Sandeep Dave.  Cell culture media, fetal 
bovine serum (FBS), and penicillin-streptomycin were purchased from Corning Cellgro.  All cell 
lines were maintained between 2x105 – 1x106 cells/mL in RPMI 1640 media containing 10% 
FBS supplemented with penicillin-streptomycin at 37 °C in a 5% CO2 incubator. 
2.2.2 Cell Viability Assays 
Cell viability was determined using the CellTiter-Glo® 2.0 system (Promega) according 
to the manufacturer’s protocol.  Cells were seeded into 96-well plates at 5,000 cells/well, treated 
with the indicated concentrations of dasatinib, saracatinib, or ponatinib (Selleck Chemicals), and 
grown at 37 °C in a 5% CO2 incubator.  All inhibitors were dissolved in DMSO with a final 
concentration of 0.1% DMSO.  After 72 h, plates were incubated at room temperature for 30 
min, 100 μL of CellTiter-Glo® 2.0 was added per well and mixed, and plates were allowed to 
equilibrate for another 10 min.  The plates were read on the Molecular Devices Spectra Max 
Gemini EM plate reader with the luminescent settings.  All data is reported as the mean ± 
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standard error of triplicate assays.  All data were fit to the standard EC50 equation and plotted 
using Sigmaplot. 
2.2.3 Whole Cell Lysate Preparation 
Cells were seeded at 2x105 cells/mL in 75 cm2 flasks and treated with dasatinib for the 
indicated times and concentrations.  Cells were harvested and centrifuged at 1,000 x g for 5 min 
at 4 °C, then washed 3 times with ice cold 1X DPBS.  Cell pellets were then lysed in M-PER + 
5X Halt Protease & Phosphatase cocktail (EDTA-free; both from Thermo Fisher Scientific), 
rotated for 10 min at 4 °C, then centrifuged at 17,000 x g for 10 min at 4 °C.  Supernatants were 
collected and protein concentration was determined using the Pierce BCA Protein Assay Kit 
(Thermo Scientific). 
2.2.4 Western Blots 
Phospho-Tyr416 SFK, phospho-Tyr527 SFK, Blk, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, 
GAPDH, phospho-Tyrosine, phospho-Syk, Syk, phospho-Erk, Erk, Aurora A kinase, Aurora B 
kinase, CDK4, and CDK6 antibodies were purchased from Cell Signaling Technologies.  The 
cyclin A, B, D, and E antibodies were purchased from Abcam.  Total SFK antibody was 
purchased from Millipore.  All secondary antibodies were purchased from GE Healthcare.  SDS-
PAGE was performed using 4-15% polyacrylamide gels (Bio-Rad) and loading 20 μg (10 μL) of 
each sample per well.  Gels were then transferred to polyvinylidene fluoride (PVDF) membranes 
overnight at 4 °C.  Membranes were blocked with 5% BSA or milk in 1X Tris-buffered saline 
(TBS) + 0.1% Tween-20 for 2 h, then incubated with 1:500-1:1000 of the primary antibody in 
the blocking solution overnight at 4 °C.  Membranes were washed with TBS + 0.1% Tween-20, 
incubated with 1:5000 HRP-conjugated secondary antibody for 1 h at room temperature, and 
washed again with TBS + 0.1% Tween-20.  Secondary antibodies were detected using the Clarity 
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Western ECL Substrate (Bio-Rad) according to the manufacturer’s protocol.  Images were 
acquired by an Alpha Innotech FluorChem FC2, using the chemiluminescent settings.  
Densitometry analysis was performed in ImageJ. 
2.2.5 Lyn Immunoprecipitation 
Lyn antibody (12.5 uL, Santa Cruz) was incubated with 100 μL of 2.5 mg/mL whole cell 
lysate (250 μg protein) and rotated overnight at 4 °C.  Protein A-Sepharose 4B beads 
(Invitrogen) were aliquoted into spin columns (Thermo Scientific) and washed with M-PER 
(Thermo Scientific).  The lysate/antibody mixtures were added to the beads and rotated at 4 °C 
for 1 h to capture antibodies.  Antibody-bound beads were washed again, and proteins were 
eluted from the beads via boiling in SDS-PAGE sample buffer. 
2.2.6 Multiplexed Inhibitor Bead (MIB) Affinity Chromatography/MS Analysis 
Kinases were isolated from cell lysates as previously described (70,132).  Briefly, cells 
were harvested by centrifugation and washed 3 times with 1X DPBS, then flash frozen in liquid 
nitrogen.  Cells were lysed in MIB Lysis Buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 0.5% 
Triton X-100, 1 mM EDTA, 1 mM EGTA, 10 mM NaF, and 2.5 mM Na3VO4, supplemented 
with protease inhibitor cocktail (Roche) and phosphatase inhibitor cocktails 2 & 3 (Sigma-
Aldrich)).  Lysates were sonicated, clarified by centrifugation, and filtered through a 0.2-μm 
syringe filter.  The amount of starting material was 5 mg protein, and was diluted to 1.25 mg/mL 
with MIB lysis buffer.  Diluted lysates were passed over a mixture of 117 μL each of the 
following kinase inhibitors conjugated to ECH Sepharose beads: Purvalanol B, VI-16832, and 
PP58, layered from top to bottom respectively.  The kinase inhibitor-bead conjugates were 
previously equilibrated in high salt buffer (50 mM HEPES pH 7.5, 1 M NaCl, 0.5% Triton X-
100, 1 mM EDTA, and 1 mM EGTA).  MIBs columns were sequentially washed with high salt 
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buffer, low salt buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 0.5% Triton X-100, 1 mM 
EDTA, and 1 mM EGTA), and SDS buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 0.5% Triton 
X-100, 1 mM EDTA, 1 mM EGTA, and 0.1% SDS).  Proteins were eluted by boiling samples in 
elution buffer (100 mM Tris-HCl pH 6.8, 0.5% SDS, and 1% β-mercaptoethanol) for 15 min 
twice.  Dithiothreitol (DTT) was added to a final concentration of 5 mM and samples were 
incubated at 60 °C for 25 min.  Samples were then cooled to room temperature on ice and 
alkylated by adding iodoacetamide to a final concentration of 20 mM and incubating for 30 min 
in the dark at room temperature.  Samples were then concentrated in 10K Amicon Ultra 
centrifugal concentrators (Millipore), followed by methanol and chloroform precipitation of 
proteins.  The final protein pellets were re-suspended in 50 mM HEPES pH 8.0 and incubated 
with trypsin at 37 °C overnight.  Residual detergent was removed by three sequential ethyl 
acetate extractions, then desalted using Pierce C-18 spin columns (Thermo Scientific) according 
to the manufacturer’s protocol.  Samples were stored at -80C until further analysis. 
2.2.7 LC/MS/MS Analysis 
Each sample was analyzed by LC-MS/MS using an Easy nLC 1000 coupled to a 
QExactive HF equipped with an Easy Spray source (Thermo Scientific).  First, samples were 
reconstituted in loading buffer (1% ACN, 0.1% formic acid), and then loaded onto a PepMap 
100 C18 column (75 μm inner diameter × 25 cm, 2 μm particle size) (Thermo Scientific).  
Peptides were separated over a gradient consisting of 5-32% mobile phase B over a 120-min 
method at a 250 nL/min flow rate, where mobile phase A was 0.1% formic acid in water and 
mobile phase B consisted of 0.1% formic acid in ACN.  The QExactive HF was operated in data-
dependent mode where the 15 most intense precursors were selected for subsequent 
fragmentation.  Resolution for the precursor scan (m/z 400-1600) was set to 120,000 with a 
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target value of 3x106 ions.  For MS/MS scans with HCD (normalized collision energy 27%), 
resolution was set to 15,000 with a target value of 2x104 ions.  Peptide match was set to 
preferred, and precursors with unknown charge or a charge state of 1 and >7 were excluded. 
2.2.8 Mass Spectrometry Data Processing and Analysis 
Raw data files were processed using MaxQuant software (version 1.5.3.17).  Data were 
searched against a reviewed human UniProt database (downloaded Feb 2017, containing 20,162 
sequences) using the integrated Andromeda search engine (229).  The following parameters were 
used to identify tryptic peptides for protein identification: up to two missed trypsin cleavage 
sites; carbamidomethylation (C) was set as a fixed modification; and oxidation (M) was set as a 
variable modification.  A false discovery rate (FDR) of 1% was used to filter all results, and 
match between runs was enabled.  Only proteins with >1 unique+razor peptide were used for 
label-free quantitation. 
Statistical analysis (ANOVA), hierarchical clustering, and principal component analysis 
were performed using Perseus software (version 1.6.0.2).  Bioinformatics analysis was 
performed using DAVID Bioinformatics Resources 6.8 functional annotation tool (230,231).  
Over-represented functional terms (UniProt biological processes) with p-value<0.05 were 
selected for further analysis.  Lists of kinases in these functional clusters were further 
investigated using STRING 10.5 (232) to construct protein networks and analyze their 
associations. 
2.2.9 Antibody Arrays 
Antibody arrays for probing proteins involved in apoptosis were purchased from Ray 
Biotech and were used according to the manufacturer’s protocol.  Images were acquired by a 
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2.3.1 ABC DLBCL cells are more sensitive to dasatinib than GCB DLBCL cells 
The ABC subtype of DLBCL is characterized by chronic BCR signaling, which is 
heavily dependent on the Src family kinases (SFKs) (9,10).  Therefore, we hypothesized that 
ABC DLBCL cells would be more sensitive to SFK inhibition than their GCB DLBCL 
counterparts.  To investigate SFKs as potential targets for the treatment of ABC DLBCL, we 
examined sensitivity to SFK inhibitors in a panel of DLBCL cell lines: Farage, HBL-1, HT, 
Karpas 422, OCI-Ly3, OCI-Ly10, and TMD8.  Of these cell lines, HBL-1, OCI-Ly3, OCI-Ly10, 
and TMD8 are classified as ABC DLBCL, and Farage, HT, and Karpas 422 are classified as 
GCB DLBCL (233).  We tested the sensitivity of these 7 cell lines to the SFK inhibitors 
dasatinib, saracatinib, and ponatinib (Figure 2.1, Table 2.1).  Interestingly, we found that the four 
ABC DLBCL cell lines are highly sensitive to dasatinib (EC50 between 6-81 nM), whereas the 
three GCB DLBCL cell lines are resistant (EC50>2,500 nM).  However, this disparity is much 
less pronounced with saracatinib and ponatinib, which are reported to be more specific for the 
SFKs than dasatinib (64,234,235). 
2.3.2 ABC DLBCL cells have higher Lyn expression than GCB DLBCL cells 
To characterize potential differences between ABC and GCB cell types, we determined 
the basal protein expression levels of several of the SFK members by western blotting (Figure 
2.2).  In general, we observed heterogeneous expression of the various SFK members across the 
panel of seven DLBCL cell lines.  However, Lyn is more highly expressed in the ABC DLBCL 
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cell lines, whereas Fyn is more highly expressed in the GCB DLBCL cell lines.  In addition, we 
noticed that the GCB DLBCL cell lines had higher levels of the inactive phospho-Y527 form of 
the SFKs.  To complement these data, we utilized a proteomics-based method to examine the 
kinome of these cells: multiplexed inhibitor beads (MIB) combined with mass spectrometry 
(MS), or MIB/MS.  The MIB/MS technique involves flowing whole cell lysates over columns of 
kinase inhibitors bound to sepharose beads (Figure 2.3) (70,132).  The immobilized kinase 
inhibitors on the MIBs broadly capture kinases based on expression and, in some instances, 
activity (236).  The captured kinases are then identified and quantified using MS.  Using the 
MIB/MS technique, we analyzed the basal kinome in our panel of 7 cell lines, and evaluated the 
relative amount of SFKs in these cells (Figure 2.4).  The relative amount of SFKs identified by 
MIB/MS closely reflect the expression we observed via western blotting, including higher Lyn 
expression in the ABC DLBCL cell lines and higher Fyn expression in the GCB DLBCL cell 
lines. 
2.3.3 Dasatinib inhibits the SFKs in both ABC and GCB DLBCL cells after short-term 
treatment 
Resistance of cells to kinase inhibitors is not uncommon, and can result from kinase 
overexpression, mutation, increased expression of efflux pumps, drug metabolism, or other 
mechanisms (237).  Therefore, we questioned whether dasatinib was effectively penetrating the 
cells and inhibiting its target, the SFKs, in both DLBCL subtypes.  We selected a representative 
cell line from each subtype: TMD8 for the ABC DLBCLs and HT for the GCB DLBCLs.  These 
cells were treated with 100 nM dasatinib or DMSO for 30 min, were lysed, and the kinomes 
were analyzed by MIB/MS (Figure 2.5).  Comparing the kinome data from the DMSO- and 
dasatinib-treated cells indicates that dasatinib affects the SFKs equivalently in both the TMD8 
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and HT cell lines, as both cell lines display reduced MIB binding of the SFKs in response to 
dasatinib treatment (Figure 2.6A).  Furthermore, western blot analysis showed that short-term 
dasatinib treatment leads to a decrease in the level of phospho-active SFKs and a decrease in 
global tyrosine phosphorylation across all seven cell lines, without changes in Lyn expression 
(Figures 2.6B and 2.6C, respectively).  These data suggest effective and similar inhibition of the 
SFKs in both DLBCL subtypes after short-term dasatinib treatment.  In addition, western blot 
analysis shows a dose-dependent decrease in phosphorylation of the SFKs and downstream 
targets of the SFKs after short-term dasatinib treatment (Figure 2.7).  Taken together, these data 
show that dasatinib is able to permeate the cell and bind to and inhibit the SFKs in both the ABC 
and GCB DLBCL cell lines. 
2.3.4 Dasatinib inhibits the SFKs in both ABC and GCB DLBCL cells after long-term 
treatment 
Another possible explanation for the differences in dasatinib sensitivity is that some of 
the SFKs may be recovering or adapting after long-term treatment with dasatinib.  To determine 
if the SFKs are becoming resistant to long-term dasatinib treatment, we utilized MIB/MS to 
assess kinome changes in the HT and TMD8 cell lines after treatment with dasatinib for 24 h 
(Figure 2.8).  Similar to the data obtained after short-term dasatinib treatment, MIB/MS analysis 
demonstrated reduced MIB binding of the SFKs in both the TMD8 and HT cell lines (Figure 
2.9A).  Western blot analysis of phospho-active SFK and global tyrosine phosphorylation also 
demonstrated SFK inhibition without impacting protein expression in all seven cell lines after 24 
h of dasatinib treatment (Figures 2.9B and 2.9C, respectively).  Using a lower dose of dasatinib, 
we also extended the treatment time to 72 h and assessed changes in the kinome via MIB/MS 
(Figure 2.10).  Even at 72 h, the SFKs show reduced MIB binding in both the TMD8 and HT cell 
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lines (Figure 2.11), indicating that even after long-term treatment with dasatinib, the SFKs in 
both ABC and GCB DLBCL cell lines remain sensitive to dasatinib inhibition. 
2.3.5 Dasatinib treatment induces changes in kinases other than the SFKs 
Due to the sustained inhibition of the SFKs after both short- and long-term treatment with 
dasatinib, we examined if inhibition of other kinases might contribute to the differential 
sensitivities observed among our cell lines.  Dasatinib is known to be a broadly selective kinase 
inhibitor (64), so we questioned the extent to which dasatinib affects non-Src-family kinases in 
our DLBCL cell lines. To evaluate this, we performed a principal component analysis (PCA) of 
the MIB/MS data from the 30-min and 24-h dasatinib treatment experiments (Figure 2.12).  
Interestingly, in the 30-min dataset, all of the HT samples cluster together and all of the TMD8 
samples cluster together, regardless of DMSO or dasatinib treatment.  However, in the 24-h 
dataset, the DMSO and dasatinib treatment groups cluster separately for each cell line.  These 
data suggest that the 24-h dasatinib treatment alters the kinome to a greater extent compared to 
the 30-min dasatinib treatment.  Comparing the 30-min and 24-hr MIB/MS analyses (Figures 2.5 
and 2.8, respectively) reveals a noticeable difference in the kinase families affected by dasatinib 
across both cell lines.  After 30 min, only the tyrosine kinase (TK) family of kinases were 
affected by dasatinib treatment in each cell line, as determined by a ±2-fold or higher change in 
MIB binding, relative to DMSO.  In contrast, after 24 h, the kinases displaying a ±2-fold or 
higher change in MIB binding not only include the TK kinase family, but also the AGC and 
CAMK families, among other kinase families.  Indeed, hierarchical clustering (ANOVA p-value 
<0.05) of the MIB/MS data from these experiments reveals several more clusters of differentially 
affected kinases at the 24-h timepoint relative to the 30-min timepoint (Figure 2.13). 
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2.3.6 Dasatinib inhibits several cell cycle kinases in ABC but not GCB DLBCL cell lines 
To further understand the differences in dasatinib sensitivity between the ABC and GCB 
DLBCL cell lines, we sought to explore the non-Src-family kinases that are affected by 
dasatinib.  These are kinases that could be impacted by dasatinib due to inhibition of signaling 
pathways downstream of the SFKs or to off-target effects of dasatinib.  Only kinases showing 
statistical significance (ANOVA p-value <0.05) and a ±2-fold change upon dasatinib treatment 
compared to DMSO were further considered.  Of the 24 kinases in the 30-min treatment groups 
that meet these criteria, 21 show reduced MIB binding in both the TMD8 and HT cell lines (the 
exceptions being CAMK4, FES, and MAP2K6).  However, in the 24-h treatment groups, 54 
kinases display various responses to dasatinib treatment in both cell lines.  To identify which 
cellular processes were enriched in this group of kinases, we performed a functional annotation 
clustering analysis (Figure 2.14A).  The predominant biological processes represented by the 54 
kinases from the 24-h MIB/MS experiment are cell cycle (23.6% of the kinases), immunity 
(23.6%), and apoptosis (18.2%).  Using STRING 10.5 (232), we constructed protein networks of 
the kinases from each of these processes to visualize how the kinases may associate with one 
another (Figure 2.14B-D).  The immunity cluster includes several kinases, namely the SFKs and 
Btk, which are known to be involved in BCR signaling and other proliferation pathways.  Many 
of the kinases in this network have decreased MIB binding in both cell lines after dasatinib 
treatment.  The apoptosis cluster contains kinases with a variety of responses in the TMD8 and 
HT cell lines.  In the cell cycle cluster, however, nearly all of the kinases have decreased MIBs 
binding in only the TMD8 cell line after dasatinib treatment, with the exception of GSG2 and 
Src, which have decreased MIBs binding in both cell lines.  Interestingly, nearly all of the 
kinases in this cluster appear to have associations with several other kinases in the cluster.  
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Moreover, the canonical SFK member, Src, is also included in this network and associates with 
CDK4.  These results implicate cell cycle kinases as possible players in mediating the sensitivity 
of ABC DLBCL cell lines to dasatinib. 
To highlight the differences in MIB binding after dasatinib treatment between the TMD8 
and HT cell lines, two sets of hierarchical clustering on the 24-h dataset were performed: 1) 
clustering based on the label-free quantification (LFQ) values of ANOVA-significant kinases 
from all samples and 2) clustering based on the MIBs binding ratios of the individual replicates 
from each cell line, filtered as described above (ANOVA-significant and 2-fold change in MIB 
binding) (Figure 2.15).  In each cluster map, there is a cluster of kinases that are inhibited in the 
TMD8 cell line upon dasatinib treatment, but relatively unchanged in the HT cell line.  There are 
12 kinases in common between these two clusters, 9 (75%) are known to be involved with cell 
cycle signaling and another 2 are implicated in preventing apoptosis (Table 2.2).  This result 
follows what we observed with the functional annotation analysis.  We assessed changes in 
activation and/or expression of selected cell cycle kinases identified in the MIB/MS analysis 
(Figure 2.16) to determine if changes in cell cycle kinases could be observed in the other ABC 
DLBCL cell lines.  Western blot analysis showed that total protein levels of Aurora kinase A, 
Aurora kinase B, CDK4, and CDK6 are decreased in the ABC DLBCL lines in response to 24-h 
dasatinib treatment.  This suggests that the sensitivity of the ABC DLBCL cell lines to dasatinib 
may be in part due to its effects on the cell cycle, which are not apparent in the GCB DLBCL 
cell lines.  Conversely, it is also possible that the reductions in cell cycle kinases is simply a 
manifestation of the ABC DLBCL cell lines’ sensitivity to dasatinib. 
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2.3.7 Dasatinib induces cell death in TMD8 but not HT cell line 
We also analyzed the effects of dasatinib on specific parameters of cell survival and 
apoptosis.  Using antibody arrays of pro- and anti-apoptotic proteins (Figure 2.17), we found that 
dasatinib induces over a 2-fold reduction in expression of the pro-survival protein survivin (gene 
name BIRC5) in the TMD8 cell line, but does not affect survivin in the HT cell line.  Survivin is 
known to interact with several of the cell cycle regulation kinases we identified by MIB/MS 
earlier, including AURKA, AURKB, CDK4, and PLK1 (238-241).  We also assayed whether or 
not dasatinib induces cell death in either of the cell lines, as opposed to growth inhibition.  We 
assessed apoptosis by staining cells with annexin-V and propidium iodide (PI) after treatment 
with dasatinib for 4 h or 24 h.  Staining was analyzed via flow cytometry (Figure 2.18).  These 
studies demonstrate that 100 nM dasatinib induces cell death within the TMD8 cell line, but not 
the HT cell line. 
 
2.4 Discussion 
Despite the fact that the current treatment for both the ABC and GCB subtypes of 
DLBCL is the same (R-CHOP), the ABC DLBCL subtype has a much worse prognosis (5,6).  
Thus, there is a need to find additional therapeutic agents for the treatment of ABC DLBCL.  In 
this study, we explored the utility of the SFK inhibitor dasatinib for the treatment of DLBCL.  
Using established cell lines, we found that, although ABC DLBCL cell lines are more sensitive 
to dasatinib than GCB DLBCL cell lines, all cells exhibit significant inhibition of the SFKs after 
both short- and long-term treatment with dasatinib.  This indicates that either signaling 
downstream of the SFKs or off-target effects of dasatinib are the likely causes of the differential 
sensitivities to dasatinib.  Considering the dependency of ABC DLBCL cell lines on BCR 
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signaling (and consequently on the SFKs), impacts on signaling downstream of the SFKs as a 
result of dasatinib treatment is probable.  Using MIB/MS and western blot analysis, we assessed 
changes in the kinome in response to dasatinib treatment, and found that several cell cycle 
kinases are downregulated in the ABC DLBCL cell lines, but not the GCB DLBCL cell lines.  
Correspondingly, we found a decrease in the cell survival protein survivin (BIRC5) and 
increased cell death in response to dasatinib in the ABC DLBCL cell line compared to the GCB 
DLBCL cell line.  Thus, our results suggest that dasatinib has an effect on cell cycle regulation in 
the ABC DLBCL cell line, which may contribute to this subtype’s enhanced sensitivity to 
dasatinib. 
It is well known that dasatinib is a promiscuous kinase inhibitor, targeting Abl, EGFRs, 
c-Kit, and other kinases in addition to the SFKs (64).  The SFK inhibitors saracatinib and 
ponatinib are reported to be more selective for the SFKs than dasatinib (64,234,235).  Our dose-
response studies demonstrate a large difference in dasatinib sensitivity between the ABC and 
GCB DLBCL cell lines, but this difference is less pronounced with saracatinib and ponatinib.  
This raises the question as to how and why the ABC DLBCLs respond more vigorously to 
dasatinib than the more selective inhibitors saracatinib and ponatinib.  Our data show higher Lyn 
expression in the ABC DLBCL cell lines and higher Fyn expression in the GCB DLBCL cell 
lines.  Interestingly, the work of Eguchi et al. provides evidence that a deficiency in Fyn protein 
can predispose cells to dasatinib sensitivity (242).  From an enzymatic activity perspective, our 
results clearly demonstrate continued inhibition of all SFK members in both DLBCL subtypes, 
even after long-term treatment with dasatinib.  Therefore, the notion that a deficiency in Fyn 
activity in the ABC DLBCL cell lines causes the sensitivity to dasatinib is unlikely, as Fyn is 
inhibited in the GCB DLBCL cell lines and yet they live.  However, it should be noted that the 
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Eguchi et al. paper focused on a deficiency of Fyn protein, not activity.  Thus, it is possible that 
the Fyn protein may play some sort of scaffolding function that impacts apoptotic pathways, 
causing differences in sensitivity to dasatinib between the ABC and GCB DLBCL cell lines. 
Several of our experiments and analyses point to a potential role of cell cycle kinases in 
dasatinib sensitivity.  We have shown that, of the kinases that display significant changes in 
MIBs binding after dasatinib treatment, many are involved in the cell cycle.  Furthermore, of the 
kinases that show reduced MIBs binding in the TMD8 cell line (ABC DLBCL) but no change in 
the HT cell line (GCB DLBCL), the majority are cell cycle kinases.  However, it is still unclear 
as to whether this inhibition of cell cycle proteins is a cause for dasatinib sensitivity or a result of 
dasatinib sensitivity.  Furthermore, it remains to be shown whether the inhibition of cell cycle 
kinases is due to inhibition of signaling downstream of the SFKs, or a consequence of an off-
target effect of dasatinib. 
Our network analysis of the kinases listed in the cell cycle functional annotation cluster 
hinted at a possible link between the SFK member Src and the cell cycle kinase CDK4.  There is 
evidence that Src can induce gene expression of cyclin D1 (243), which is a major activator of 
CDK4 and CDK6 (244,245).  If this relationship exists in our ABC DLBCL cell lines, it makes 
sense that the changes we observe in the cell cycle kinase expression levels (particularly CDK 4 
and CDK6) are not seen at 30 min, but rather at 24 h.  In addition, there is evidence that some 
cells can proliferate in the absence of the cyclin D-CDK4/6 axis (246).  Furthermore, a study in 
the GCB DLBCL cell line OCI-Ly18 demonstrated that OCI-Ly18 expresses cyclin D3, but not 
cyclins D1 and D2, and that knockdown of cyclin D3 did not affect cell viability or proliferation 
(247).  Thus, it is possible that, in the ABC DLBCL cell lines, dasatinib-induced inhibition of the 
SFKs leads to inhibition of the cyclin D-CDK4/6 axis, which results in growth inhibition and cell 
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death.  Moreover, it is possible that a lack of dependency on the cyclin D-CDK4/6 axis in the 
GCB DLBCL cell lines may contribute to their resistance to dasatinib.  This should be explored 
in future studies. 
It should be noted that several of the cell cycle kinases we identified are capable of 
interacting with, and even regulating, each other.  For example, Polo-like kinase 1 (PLK1) can 
interact with AURKA, AURKB, BUB1, CDC7, or MYT1 to help regulate mitotic entry and 
spindle assembly (248-252), and AURKA can even activate PLK1 (249).  In addition, survivin is 
known to interact with several of the cell cycle regulation kinases we identified, including 
AURKA, AURKB, CDK4, and PLK1 (238-241).  Further studies should explore the 
mechanisms by which dasatinib leads to inhibition of these cell cycle proteins, and if inhibition 
of one may lead to the inhibition of others. 
The Aurora kinases (AURKA and AURKB) are among the cell cycle kinases we 
identified as downregulated in the ABC DLBCL subtype after dasatinib treatment.  Interestingly, 
there are ongoing studies for the use of Aurora kinase inhibitors in the treatment of DLBCL, 
particularly for more aggressive forms of the disease (253-255), and in general the Aurora 
kinases are gaining recognition as potential targets for the treatment of other cancers (256,257).  
Furthermore, some studies have demonstrated synergy between Aurora kinase inhibitors and 
dasatinib (258,259), and have even suggested that inhibition of the Aurora kinases can overcome 
resistance to other tyrosine kinase inhibitors (260).  Considering the promiscuity of dasatinib and 
that there is currently no evidence in the literature to suggest interactions between the SFKs and 
the Aurora kinases, it is possible that dual inhibition of the SFKs and the Aurora kinases in the 
ABC DLBCL cell lines, but not the GCB DLBCL cell lines, causes the disparity in dasatinib 
sensitivity we have observed.   
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To our knowledge, this is the first study to demonstrate downregulation of several cell 
cycle kinases in response to dasatinib treatment in DLBCL.  It is possible that some indirect or 
“downstream” effect of dasatinib leads to their inhibition rather than direct inhibition of these 
cell cycle kinases.  Indeed, in several studies that examined direct targets of dasatinib in vitro and 
in cells, none identified the cell cycle kinases we found (64,261,262).  However, one study in 
leukemia cells determined that CDK2 and CDK8 genes, among other cell cycle genes, were 
down-regulated in response to dasatinib treatment (227).  It is important to note that inhibition of 
cell cycle kinases was predominantly observed in the ABC DLBCL cell lines, and not the GCB 
DLBCL cell lines.  Therefore, it is likely that some mechanism other than direct inhibition by 
dasatinib is taking place, and it is of great interest to further examine this mechanism to better 
understand the sensitivity of the ABC DLBCL cell lines to dasatinib.  This study clearly 
demonstrates that dasatinib has potent activity on the ABC DLBCL subtype, which warrants 
















Farage >2,500.0 >10.0 >1,000.0 
HT >2,500.0 >10.0 >1,000.0 
Karpas 422 >2,500.0 >10.0 >1,000.0 
HBL-1 81.4 5.7 272.1 
OCI-Ly3 6.7 0.7 88.8 
OCI-Ly10 34.3 3.5 78.1 
TMD8 20.5 2.4 14.9 
 
Table 2.1: EC50 values of dasatinib, saracatinib, and ponatinib in DLBCL cell lines 






Protein Name Major Cellular Pathways 
ACVR1B Activin receptor type-1B 
Cytokine signaling 
(activins) 
AURKA Aurora kinase A 
Cell cycle regulation 
(mitotic spindle) 
AURKB Aurora kinase B 




protein kinase BUB1 
Cell cycle regulation 
(spindle assembly checkpoint and 
chromosome alignment) 
CDC7 
Cell division cycle 7-related protein 
kinase 
Cell cycle regulation 
(promotes G1/S phase transition) 
CDK4 Cyclin-dependent kinase 4 
Cell cycle regulation 
(promotes G1/S phase transition) 
CDK6 Cyclin-dependent kinase 6 
Cell cycle regulation 
(promotes G1/S phase transition) 
CHUK 
Inhibitor of nuclear factor kappa-B 




Dual specificity mitogen-activated 
protein kinase kinase 5 
MAPK signaling 
(protection from apoptosis) 
PKMYT1 
Membrane-associated tyrosine- and 
threonine-specific cdc2-inhibitory 
kinase 
Cell cycle regulation 
(inhibits G2/M checkpoint) 
PLK1 Serine/threonine-protein kinase PLK1 
Cell cycle regulation 
(M phase progression) 
TTK Dual specificity protein kinase TTK 
Cell cycle regulation 
(mitotic checkpoint) 
 
Table 2.2: Differential expression of kinases revealed by hierarchical clustering 
Kinases that are inhibited in TMD8 but not HT after 100 nM treatment with dasatinib for 24 h.  





Figure 2.1: SFK inhibitor dose-response curves in DLBCL cell lines 
Dose-response curves of cell viability for the panel of DLBCL cell lines treated with (A) 
dasatinib, (B) saracatinib, or (C) ponatinib.  Cells were treated with the indicated concentration 




Figure 2.2: SFK member expression in DLBCL cell lines 
Relative protein expression of the individual SFK members in the panel of DLBCL cell lines, as 





Figure 2.3: Schematic of proteomics workflow 
Schematic representation of the MIB/MS technique.  Cells are lysed, then lysates are flowed over 
a column of kinase inhibitor-bound beads to capture kinases.  Bound kinases are then eluted, 





Figure 2.4: Active SFKs in DLBCL cell lines 
Relative expression of the individual SFK members in the panel of DLBCL cell lines, as 
determined by MIB/MS binding.  Data are shown as normalized to the average of each SFK 
across all 7 cell lines.  Red indicates higher MIBs binding, blue indicates less MIBs binding 







BLK 2.52     0.50     1.18     0.18     0.15     1.71     0.77     
FGR 0.09     -       0.04     0.01     0.02     5.41     1.44     
FRK 5.51     0.07     0.38     0.74     0.28     0.01     -       
FYN 0.11     0.05     0.02     0.17     0.57     4.59     1.48     
HCK 0.55     0.00     1.38     5.07     0.00     0.00     0.00     
LCK 0.15     2.74     0.06     0.00     0.00     1.72     2.32     
LYN 1.24     0.74     0.88     2.89     0.37     0.70     0.18     
SRC 1.81     0.00     0.33     0.15     0.52     3.14     1.04     






Figure 2.5: MIB/MS binding after treatment with 100 nM dasatinib for 30 min 
TMD8 and HT cells were treated with DMSO or 100 nM dasatinib for 30 min, and kinome changes were analyzed by MIB/MS in 
three independent experiments.  Data are shown as ratios of kinase binding in the dasatinib-treated cells relative to the DMSO-treated 








































































































































































































































































































Figure 2.6: SFKs are inhibited by dasatinib after 30 min treatment 
After treatment with 100 nM dasatinib for 30 min, cells were lysed and SFK inhibition was 
assessed via (A) changes in binding of the SFKs using the MIB/MS technique (<1 and >1 denote 
decreased and increased MIB binding of kinases from lysates, respectively), (B) changes in SFK 
phosphorylation status (western blot), or (C) changes in global phospho-tyrosine residues 




Figure 2.7: SFKs are inhibited by short-term dasatinib treatment in a dose-dependent 
manner 
(A) Western blots of SFK downstream targets after 30 min treatment with dasatinib at the 
indicated concentrations.  Western blots shown were from the OCI-Ly3 cell line.  (B) Western 
blot of phospho-active Lyn from cells treated with dasatinib at the indicated concentrations for 
30 min.  After dasatinib treatment, cells were lysed and Lyn was immunoprecipitated from whole 







Figure 2.8: MIB/M4S binding after treatment with 100 nM dasatinib for 24 h 
TMD8 and HT cells were treated with DMSO or 100 nM dasatinib for 24 h, and kinome changes were analyzed by MIB/MS in three 
independent experiments.  Data are shown as ratios of kinase binding in the dasatinib-treated cells relative to the DMSO-treated cells.  














































































































































































































































































Figure 2.9: SFKs are inhibited by dasatinib after 24 h treatment 
After treatment with 100 nM dasatinib for 24 h, cells were lysed and SFK inhibition was 
assessed via (A) changes in binding of the SFKs using the MIB/MS technique (<1 and >1 denote 
decreased and increased MIB binding of kinases from lysates, respectively), (B) changes in SFK 







Figure 2.10: MIB/MS binding after treatment with 100 nM dasatinib for 72 h 
TMD8 and HT cells were treated with DMSO or 10 nM dasatinib for 72 h, and kinome changes were analyzed by MIB/MS in three 
independent experiments.  Data are shown as ratios of kinase binding in the dasatinib-treated cells relative to the DMSO-treated cells.  























































































































































































































































































































Figure 2.11: SFKs are inhibited by dasatinib after 72 h treatment 
After treatment with 10 nM dasatinib for 72 h, cells were lysed and SFK inhibition was assessed 
via changes in binding of the SFKs using the MIB/MS technique (<1 and >1 denote decreased 





Figure 2.12: Long-term dasatinib treatment has more of an impact on the kinome than 
short-term dasatinib treatment 
Principal component analysis of kinases identified by MIB/MS after treatment with 100 nM 





Figure 2.13: Dasatinib treatment induces different kinome responses 
Hierarchical clustering of label-free quantification (LFQ) values for kinases identified by 
MIB/MS after treatment with 100 nM dasatinib for (A) 30 min (231 quantifiable kinases) or (B) 





Figure 2.14: Functional annotation analysis of 24-h MIBs/MS results 
(A) Functional annotation clusters of ANOVA-significant kinases with ±2-fold change or higher 
in MIB binding after dasatinib treatment.  Assessment was generated using the DAVID 
functional annotation tool (230,231) and selecting for Uniprot keyword annotation terms for 
biological processes.  (B-D) Association networks of proteins from the (B) cell cycle, (C) 
immunity, and (D) apoptosis clusters were analyzed using the online STRING (232) tool.  Line 




Figure 2.15: Hierarchical clustering of kinases inhibited in the TMD8 but not HT cell line 
after treatment with dasatinib 
(A) Hierarchical clustering of label-free quantification (LFQ) values for kinases identified by 
MIB/MS after treatment with 100 nM dasatinib for 24 h (205 quantifiable kinases), zoomed in to 
show kinases inhibited by dasatinib in the TMD8 cell line.  Red = positive z-score; green = 
negative z-score.  (B) Hierarchical clustering of MIBs binding ratios of kinases identified by the 
MIB/MS technique after treatment with 100 nM dasatinib for 24 h.  Kinases were filtered for 
those that were statistically significant (ANOVA p<0.05) and had binding ratios (dasatinib-
treated relative to DMSO-treated) of less than 0.5 or greater than 2.0 in at least one of the cell 
lines.  Hierarchical clustering was performed on 54 kinases, including all 9 SFK members.  Red 





Figure 2.16: Decreased expression of cell cycle kinases in the ABC DLBCL cell lines after 
treatment with dasatinib 
Western blot analysis of several cell cycle kinases in the panel of DLBCL cell lines after 





Figure 2.17: Dasatinib treatment decreases survivin expression in TMD8 but not HT cells 
(A) Map of the proteins targeted by the apoptotic antibody arrays.  Pink = pro-apoptotic, blue = 
anti-apoptotic/pro-survival, purple = mixed activity.  (B) Antibody arrays of anti- or pro-
apoptotic proteins of HT and TMD8 cells treated with 100 nM dasatinib for 24 h.  Red boxes 





Figure 2.18: Dasatinib treatment induces cell death in TMD8 but not HT cell lines 
Quantification of flow cytometry analysis of cells stained with annexin-V (AnnV) and propidium 
iodide (PI) after treatment with 100 nM dasatinib for 4 or 24 h.  Dead = AnnV+, PI+; Viable = 






CHAPTER 3: THE SRC FAMILY KINASES AS PROTEASOME REGULATORS IN 
ACTIVATED B-CELL DIFFUSE LARGE B-CELL LYMPHOMA 
 
3.1 Introduction 
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease that consists of 
different molecular subtypes based on gene expression profiling.  Patients with DLBCL can be 
categorized into two clinically relevant subtypes: activated B-cell (ABC) and germinal center B-
cell (GCB) (4).  However, despite these distinctions, patients with ABC or GCB DLBCL are 
treated identically using a chemotherapy regimen called R-CHOP, which includes rituximab, 
cyclophosphamide, doxorubicin, vincristine, and prednisone.  Although the R-CHOP regimen 
has a relatively high cure rate for patients with GCB DLBCL (2,8), patients with ABC DLBCL 
generally have a much poorer prognosis (5,6).  Therefore, there is great interest in developing 
additional therapeutic agents for the treatment of ABC DLBCL. 
As part of the distinctions between the ABC and GCB DLBCL subtypes, there are certain 
pathways that are known to be overactive in ABC, but not GCB, DLBCL.  In particular, chronic, 
overactive signaling through the B-cell receptor (BCR) and the NF-κB pathway are hallmarks of 
the ABC but not the GCB DLBCL subtype (9,10).  Signaling through the BCR can trigger many 
pro-survival and proliferation pathways, including initiation of the anti-apoptotic NF-κB 
pathway (10,263).  This signaling is heavily dependent upon three key nonreceptor tyrosine 
kinases: Lyn, a member of the Src family kinases (SFKs); Syk; and Btk (32).  Of these three, 
Lyn is first in line to help mediate BCR signaling (32-34).  In addition, Lyn and the other SFKs 
play a role in signaling from many receptors, facilitating several proliferation, survival, and cell 
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motility pathways (22,23,29).  Based on SFK involvement in these signaling pathways, it is not 
surprising that the SFKs have been implicated in progression and drug resistance in many 
cancers, including lymphoma (9,29,37,38).  Therefore, the SFKs could be a viable target for the 
treatment of ABC DLBCL.  In fact, some studies have demonstrated the potential for targeting 
the SFKs in lymphoma, showing that the SFK inhibitor dasatinib is capable of inhibiting 
proliferation in certain DLBCL and other B-cell lymphoma cell lines (9,37,38,215). 
The cell’s natural protein degradation machinery, the proteasome, has also been 
implicated in cancer and drug resistance due to its degradation of various antitumor-related 
proteins (11,180,181,216).  In regards to DLBCL, the anti-apoptotic NF-κB signaling pathway is 
heavily dependent upon the proteasome because negative regulators of the NF-κB pathway are 
degraded by the proteasome.  Previous work from our lab demonstrated that proteasome specific 
activity is higher in DLBCL cell lines compared to healthy, primary B-cells (213).  This suggests 
the proteasome may also be of use as a target for the treatment of ABC DLBCL.  In fact, the 
proteasome inhibitor bortezomib is currently in clinical trials for the treatment of ABC DLBCL.  
When combined with standard chemotherapy, bortezomib has a significant effect on ABC 
DLBCL but not on GCB DLBCL patients (12,190). 
The proteasome is a proteolytic complex found in the nucleus and cytoplasm of all 
eukaryotic cells.  It is generally comprised of a 20S core particle and one or two regulatory 
particles.  The 20S core particle is a barrel-shaped structure comprised of two heteroheptameric 
outer α-rings and two heteroheptameric inner β-rings (164).  It has three distinct proteolytic 
activities: caspase-like (CaL), trypsin-like (TL), and chymotrypsin-like (ChL), which are 
provided by its β1, β2, and β5 subunits, respectively (163).  The 20S core particle can be capped 
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on either end by one of four possible regulatory particles: PA700 (also known as 19S), PA28αβ, 
PA28γ, and PA200 (163). 
Interestingly, there is some evidence of potential mechanistic links between the SFKs and 
the proteasome.  For example, the SFKs are involved in many signaling pathways that feed into 
the proteasome, such as NF-κB and MAPK/ERK signaling (217-220).  In addition, the SFKs 
themselves are degraded by the proteasome (221,222).  Moreover, the SFKs can promote 
Jak/STAT and EGF/MAPK signaling (226,227), both of which have been demonstrated to 
activate the proteasome (223-225).  A recent study by Crawford et al. (192) demonstrated that 
treatment of chronic myelogenous leukemia cells with tyrosine kinase inhibitors and proteasome 
inhibitors produces a synergistic effect.  Thus, it is possible that there is cross talk between the 
SFKs and the proteasome.  However, to our knowledge, direct links between SFK activity and 
proteasome activation have not been studied. 
We hypothesized that the SFKs activate the proteasome.  Furthermore, since the 
proteasome and the SFKs are important particularly for ABC DLBCL over GCB DLBCL, we 
were particularly interested in studying the differences in SFK-mediated proteasome activation 
between the two subtypes.  Using a set of novel peptide probes for the proteasome’s three 
catalytic activities (213), we found that treatment with the SFK inhibitor dasatinib results in 
reduced proteasome activity in the ABC DLBCL cell lines tested, but has no effect on the GCB 
DLBCL cell lines.  Furthermore, this reduction in activity is accompanied by a reduction in the 
amount of 19S regulatory particle in isolated proteasomes.  However, the total levels of 19S 
regulatory particle are unchanged in whole lysates, indicating either a dissociation or disrupted 




3.2 Materials and Methods 
3.2.1 Materials 
Dasatinib was purchased from SelleckChem.  All other chemicals were from Fisher or 
Sigma unless otherwise noted. 
3.2.2 Whole Cell Lysate Preparation 
Approximately 72 h after seeding at 2x105 cells/mL in 75 cm2 flasks, cells from each cell 
line were used to prepare whole cell lysate and proteasome-enriched extracts (cells were split 
50/50 for the two preparations after washing with 1X DPBS).  Cells were harvested and 
centrifuged at 1,000 x g for 5 min at 4 °C, then washed 3 times with ice cold 1X DPBS.  Cell 
pellets for the whole lysate preparation were then resuspended in M-PER + 5X Halt Protease & 
Phosphatase cocktail (EDTA-free), both purchased from Thermo Scientific, rotated for 10 min at 
4 °C, then centrifuged at 17,000 x g for 10 min at 4 °C.  Supernatants were collected and protein 
concentration was determined using the Pierce BCA Protein Assay Kit from Thermo Scientific. 
3.2.3 Proteasome Enrichment 
Approximately 72 h after seeding at 2x105 cells/mL in 75 cm2 flasks, cells from each cell 
line were used to prepare whole cell lysate and proteasome-enriched extracts (cells were split 
50/50 for the two preparations after washing with 1X DPBS).  Cells were harvested and 
centrifuged at 1,000 x g for 5 min at 4 °C, then washed 3 times with ice cold 1X DPBS.  Cell 
pellets for the proteasome enrichment preparation were then resuspended in 4 volumes 
homogenization buffer (50 mM Tris, 250 mM sucrose, 5 mM MgCl2, 1 mM ATP, 1 mM DTT, 
0.5 mM EDTA, pH 7.5) with 0.025% digitonin, incubated on ice for 10 min, then centrifuged at 
17,000 x g for 10 min at 4 °C.  The supernatant was collected and ultracentrifuged at 180,000 x g 
for 4 h at 4 °C.  The supernatant was removed and the pellet resuspended in homogenization 
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buffer without digitonin.  Protein concentration was determined using the Pierce BCA Protein 
Assay Kit from Thermo Scientific. 
3.2.4 Proteasome Activity Assays 
The activities of all proteasome-enriched extracts were determined in assay buffer (50 
mM Tris pH 7.5, 40 mM KCl, 4 mM MgCl2, 1 mM ATP, 1 mM EDTA) and 0.05% bovine 
serum albumin (BSA) with 0.5 µM ChL-488, 1 µM TL-550, and 1 µM CaL-633 proteasome 
sensors, as described previously (213,264).  The reactions were initiated with 10 µg of sample 
and the reaction progress monitored for 4 h at room temperature.  Control assays without 
proteasome were run to ensure that the fluorescent change was due to proteasome activity and 
not hydrolysis.  Fluorescence was monitored on a Molecular Devices Spectra Max Gemini EM 
plate reader with excitation wavelengths of 490 nm, 550 nm, and 625 nm and emission 
wavelengths of 515 nm, 575 nm, and 655 nm, respectively.  Sigmaplot 12 software (serial 
number 775206611) was used for the analysis of all data.  The rate of each assay was determined 
using a linear fit to the first 10% of substrate consumption.  All data are reported as the mean ± 
standard deviation of triplicate assays. 
3.2.5 Western Blots 
Proteasome 20S α7 and 19S Rpn13 antibodies were purchased from Cell Signaling 
Technologies.  Proteasome 20S β1, 20S β2, and 20S β5 antibodies were purchased from Enzo 
Life Sciences.  Proteasome 20S β5i antibody was purchased from Thermo Fisher Scientific.  All 
secondary antibodies were purchased from GE Healthcare.  SDS-PAGE was performed using 4-
15% SDS Tris-HCl gels (Bio-Rad) and loading 20 μg (10 μL) of each sample per well.  Gels 
were then transferred to polyvinylidene fluoride (PVDF) membranes overnight at 4 °C.  
Membranes were blocked with 5% BSA in 1X Tris-buffered saline (TBS) + 0.1% Tween-20 for 
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2 h, then incubated with 1:500-1:1000 of the primary antibody in the blocking solution overnight 
at 4 °C.  Membranes were washed with TBS + 0.1% Tween-20, incubated with 1:5000 HRP-
conjugated secondary antibody for 1 h at room temperature, and washed again with TBS + 0.1% 
Tween-20.  Secondary antibodies were detected using the Clarity Western ECL Substrate (Bio-
Rad) according to the manufacturer’s protocol.  Images were acquired using an Alpha Innotech 
FluorChem FC2 using the chemiluminescent settings.  Densitometry analysis was performed in 
ImageJ. 
3.2.6 Trypsin digestion and phosphopeptide enrichment 
For phosphoproteome analysis, 4 volumes of cold acetone were added to 1 mg of each 
lysate for protein precipitation.  The samples were then reconstituted in 7 M urea, reduced, 
alkylated, and digested overnight with trypsin (Promega).  Peptides were desalted using Sep-Pak 
C18 cartridges (Waters) according to the manufacturer’s protocol, then dried down and stored at 
-80 °C until further use.  Phosphopeptide enrichment was performed using the 200 μL TiO2 Spin 
Columns from GL Sciences.  Peptide samples were reconstituted with 80/20 ACN/lactic acid in 
1% TFA, then loaded onto the TiO2 spin column prewashed with 80% ACN, 1% TFA.  Peptides 
were washed once with 80/20 ACN/lactic acid in 1% TFA and twice with 80% ACN, 1% TFA.  
Retained peptides were eluted twice with 20% ACN, 5% NH4OH and acidified to pH <4 with 
formic acid.  All phosphopeptide eluates were desalted using C18 Spin Columns (Thermo 
Fisher) then dried down and stored at -80 °C until further use. 
3.2.7 LC/MS/MS Analysis 
Each sample was analyzed by LC-MS/MS using an Easy nLC 1000 coupled to a 
QExactive HF equipped with an Easy Spray source (Thermo Scientific).  First, samples were 
reconstituted in loading buffer (1% ACN, 0.1% formic acid), and then loaded onto a PepMap 
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100 C18 column (75 μm inner diameter × 25 cm, 2 μm particle size) (Thermo Scientific).  
Peptides were separated over a gradient consisting of 5-32% mobile phase B over a 120-min 
method at a 250 nL/min flow rate, where mobile phase A was 0.1% formic acid in water and 
mobile phase B consisted of 0.1% formic acid in ACN.  The QExactive HF was operated in data-
dependent mode where the 15 most intense precursors were selected for subsequent 
fragmentation.  Resolution for the precursor scan (m/z 400-1600) was set to 120,000 with a 
target value of 3x106 ions.  For MS/MS scans with HCD (normalized collision energy 27%), 
resolution was set to 15,000 with a target value of 2x104 ions.  Peptide match was set to 
preferred, and precursors with unknown charge or a charge state of 1 and >7 were excluded. 
3.2.8 Mass Spectrometry Data Processing and Analysis 
Raw data files were processed using MaxQuant software (version 1.5.3.17).  Data were 
searched against a reviewed human UniProt database (downloaded Feb 2017, containing 20,162 
sequences) using the integrated Andromeda search engine (229).  The following parameters were 
used to identify tryptic peptides for protein identification: up to two missed trypsin cleavage 
sites; carbamidomethylation (C) was set as a fixed modification; and oxidation (M) was set as a 
variable modification.  A false discovery rate (FDR) of 1% was used to filter all results, and 
match between runs was enabled.  Only proteins with >1 unique+razor peptide were used for 
label-free quantitation.   
 
3.3 Results 
3.3.1 Dasatinib treatment reduces proteasome activity in ABC DLBCL cells 
We first assessed the potential for the SFKs to regulate the proteasome by examining the 
effects of treatment with the SFK inhibitor dasatinib.  To do this, we utilized a set of novel 
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peptide probes for measuring proteasome activities.  The 20S core particle of the proteasome has 
three proteolytic activities, caspase-like (CaL), trypsin-like (TL), and chymotrypsin-like (ChL), 
which are provided by its β1, β2, and β5 subunits, respectively (163).  We have previously 
developed three distinct fluorogenic peptide-based sensors that can simultaneously measure each 
of these activities (213) (Figure 1.11).  Each sensor is comprised of a fluorophore, a peptide 
specific for one of the three proteasome activities, and a quencher (acid blue 40, abbreviated 
AB40) (214).  The ChL, TL, and CaL sensors have the following sequences: FAM-His-His-Ser-
Leu-Lys(AB40), TAMRA-Leu-Arg-Arg-Lys(AB40), and DyLight633-nLeu-Pro-nLeu-Asp-
Lys(AB40), respectively.  In the intact sensor, the fluorescence of the fluorophore is internally 
quenched by a covalently appended dye (AB40), but upon proteolysis of the peptide, the 
fluorophore dissociates from the quencher and becomes fluorescent.  In order to simultaneously 
measure each proteolytic activity, each sensor has a photophysically distinct fluorophore. 
Cells were treated with our without dasatinib for 72 h, proteasomes were isolated, and 
proteasome activity was measured using the aforementioned probes, as described previously 
(213).  To ensure our measurements were not compounded by significant cell death due to 
dasatinib, we selected doses for each cell line such that at least 75% of the cells were viable 
(Table 3.1).  These doses were chosen based on dose-response curves performed in earlier work 
(Chapter 2).  After assessing proteasome activity in response to dasatinib treatment, we found 
that dasatinib treatment induces significant reductions in proteasome ChL, TL, and CaL activity 
in the ABC DLBCL cell lines, but has no effect in the GCB DLBCL cell lines (Figure 3.1).  In 
addition, this reduction in proteasome activity appears to be both time- and dose-dependent 





3.3.2 Dasatinib treatment does not significantly alter proteasome catalytic subunit protein 
expression 
In order to assess the cause of the effects of dasatinib treatment on the proteasome, we 
first questioned whether dasatinib has a direct effect on proteasome activity.  Purified 
proteasomes were mixed with varying concentrations of dasatinib, then proteasome activity was 
assessed as before.  These studies demonstrated that dasatinib has no direct effect on proteasomal 
activity (data not shown). 
Another possible explanation for the changes in proteasome activity is a change in the 
expression levels of its three catalytic subunits, β1, β2, and β5, which confer its CaL, TL, and 
ChL activities, respectively (163).  We therefore assessed potential changes in protein expression 
of each of the constitutive proteasome catalytic subunits in response to dasatinib treatment 
(Figure 3.3).  Expression levels were assessed in both isolated proteasomes (Figure 3.3A) and 
whole lysates (Figure 3.3B), using expression of the 20S α7 subunit as a loading control for total 
proteasome.  Although there appears to be a minimal change in expression of the β5 proteasome 
subunit with dasatinib treatment in the ABC DLBCL cell lines, there does not appear to be any 
significant changes in expression of the β2 and β1 subunits in response to dasatinib treatment.  In 
immune cells, the β1, β2, and β5 subunits can be replaced by the immunoproteasome subunits 
β1i, β2i, and β5i, respectively (163,165).  This produces a proteasome with altered cleavage 
patterns favoring the production of peptides involved in antigen presentation (163,166,167).  
Since we found the ChL (β5/β5i) activity to be most dominant in our cell lines, and dasatinib 
induces the most robust changes in ChL (β5/β5i) activity, we also assessed changes in expression 
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of the β5i subunit of the immunoproteasome (Figure 3.3).  Similar to the constitutive proteasome 
catalytic subunits, no significant change in β5i subunit expression was observed. 
3.3.3 Dasatinib treatment reduces 19S regulatory particle levels in isolated proteasomes 
but not whole lysates 
Binding of the 19S regulatory particle is known to enhance proteasome activity 
(265,266).  Considering the observed changes in proteasome activity across all three catalytic 
activities in the ABC DLBCL cell lines in response to dasatinib, it is possible that this reduced 
proteasomal activity may be due to changes in the 19S regulatory particle.  Therefore, we 
assessed changes in expression of Rpn13, a subunit of the 19S regulatory particle, in both 
isolated proteasomes and whole lysates (Figure 3.4).  Interestingly, the isolated proteasomes 
from dasatinib-treated ABC DLBCL cell lines show a decrease in the amount of Rpn13, 
compared to DMSO controls.  We at first thought this could indicate a general downregulation of 
Rpn13 expression.  However, western blotting of the corresponding whole lysates demonstrates 
no change in Rpn13 expression between DMSO and dasatinib treatment in any of the cell lines.  
Therefore, it is possible the proteasome is undergoing a structural change that affects binding of 
the 19S regulatory particle to the 20S core particle.  We have attempted immunoprecipitation and 
Native-PAGE experiments to confirm this notion.  However, to date we have been unsuccessful 
in optimizing these techniques.  Some of the challenges we have encountered include 
interference of the sepharose beads for immunoprecipitation with western blotting, as well as 
issues of similar molecular weights between the immunoprecipitation antibody light chains and 
proteasome subunits.  In addition, we have yet to identify ideal gel polyacrylamide and running 
buffer concentrations to produce adequate separation of the 20S and 19S particles with sufficient 
band sharpness using Native-PAGE. 
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3.3.4 Dasatinib treatment leads to changes in proteasome subunit phosphorylation 
To better understand the potential structural changes that might be occurring in the 
proteasome in response to dasatinib, a kinase inhibitor, we decided to evaluate changes in the 
phosphoproteome.  We selected one representative cell line from each subtype: HT for the GCB 
DLBCL cell lines and TMD8 for the ABC DLBCL cell lines.  Cells were treated with 100 nM 
dasatinib for 30 min, lysed, and the lysates subjected to phosphoproteomics analysis via mass 
spectrometry.  We searched the results for proteasome proteins, and found phosphorylation 
results from 10 proteasome subunits and 2 proteasome-related proteins (Table 3.2).  The 
identified proteasome subunits are two members of the 19S regulatory particle and a subunit 
from the 20S core particle.  The two proteasome-related proteins identified are PSMF1, a known 
proteasome inhibitor (267,268), and PSMG2, a proteasome assembly chaperone (269).  Nearly 
all of the identified phosphorylation sites have been reported previously (270-275), with Ser 152 
of PSMF1 (PI31) being the exception.  Comparing the HT cell line to the TMD8 cell line, 
changes in phosphorylation are most prominent for the proteasome 19S base subunit PSMD1 




Since patients with ABC DLBCL have a poorer prognosis than their GCB DLBCL 
counterparts (5,6), there is great interest in identifying effective drug targets for the treatment of 
this subtype.  Both the SFKs and the proteasome are critical for signaling in the ABC DLBCL 
subtype, particularly in regards to overactive NF-κB signaling (10,11,32,180,263).  Although 
there is evidence for potential cross talk between the SFKs and the proteasome, direct links 
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between these proteins have yet to be studied.  In this study, we explored the potential role of the 
SFKs as regulators of the proteasome.  Treatment of a panel of DLBCL cell lines with the SFK 
inhibitor dasatinib results in a marked decrease in the proteasome’s ChL, TL, and CaL activities 
for the ABC DLBCL cell lines, whereas no changes are observed in the GCB DLBCL cell lines.  
Biochemical analyses demonstrate that while there is minimal change in expression of the β5 
proteasome subunit, which is responsible for the proteasome’s ChL activity, dasatinib treatment 
induces a decrease in expression of the proteasome 19S regulatory particle in isolated 
proteasomes.  However, 19S expression remains unchanged in whole lysates, indicating that the 
SFKs could regulate proteasome assembly, possibly via phosphorylation or through a chaperone 
protein that helps assemble or stabilize proteasome complexes.  A phosphoproteomics analysis 
demonstrated changes in the phosphorylation status of several proteasome subunits and 
proteasome-related proteins in response to dasatinib treatment.  Our working hypothesis is that 
the SFKs, either directly or indirectly via proteasome-related proteins, help promote assembly or 
stability of the 20S core and 19S regulatory proteasome particles (Figure 3.5). 
Several studies have examined the mechanism by which the 19S regulatory particle binds 
to the proteasome 20S core particle.  The 19S regulatory particle is comprised of 18 different 
subunits, six of which are ATPases used for ATP-dependent protein unfolding (164).  These six 
ATPases form the base of the 19S core particle and directly bind to the outer α-ring of the 20S 
core particle (276-278).  In addition, the 19S lid subunit Rpn6 is described as having a pivotal 
role in stabilizing the interaction between the proteasome 20S core particle and 19S regulatory 
particle (279).  There is evidence of phosphorylation of several of these key binding subunits, 
and some phosphorylation sites have been demonstrated to enhance proteasome activity 
(272,280-283).  Unsurprisingly, the assembly of the 20S core particle and 19S regulatory particle 
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is facilitated by several chaperone proteins, such as Hsp90 (284), Nas6 (285), and the 
heterodimeric complex of PSMG1 (also known as PAC1) and PSMG2 (also known as PAC2) 
(269).  Our phosphoproteomics data demonstrated changes in phosphorylation of Thr18 of the 
chaperone PSMG1 in response to dasatinib treatment, with a fold change of 1.40 for the HT cell 
line and 0.34 for the TMD8 cell line.  Although other researchers have also identified this 
phosphorylation site (271), to our knowledge no functional analyses of its role in PSMG1 
activity have been performed.  It is possible that phosphorylation of Thr18 on PSMG1 activates 
the chaperone, thus promoting proper proteasome assembly.  If this enhanced phosphorylation is 
present across all of the GCB DLBCL cell lines and reduced in the ABC DLBCL cell lines with 
dasatinib treatment, it could explain (at least in part) the differences in proteasome structure 
between the two subtypes in response to dasatinib.  Future studies should explore changes in 
phosphorylation of Thr18 on PSMG1 after dasatinib treatment in all seven of the cell lines used 
in this study. 
Dasatinib treatment also induces changes in phosphorylation status of Thr273 of the 19S 
regulatory particle base subunit Rpn2 (PSMD1), with a reduction of 0.67 in the HT cell line and 
an increase of 1.72 in the TMD8 cell line.  Interestingly, Lee et al. demonstrated that 
phosphorylation of Thr273 by p38 MAPK causes inhibition of the proteasome (286), which 
could help explain the reduction in proteasome activity observed in the ABC DLBCL cell lines 
after dasatinib treatment.  This should be confirmed by assessing phosphorylation of Thr273 on 
Rpn2 in all seven cell lines used in this study.  On another note, one of the major functions of the 
Rpn2 subunit is docking for the ubiquitin-binding Rpn13 subunit (287-289).  However, crystal 
structures demonstrate that the Thr273 residue is far from the Rpn13 binding site of Rpn2 (289), 
making it unlikely that phosphorylation at this residue would impact Rpn13 binding.  
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Nevertheless, it is worth noting that the representative 19S subunit we examined in this study 
was Rpn13, and it is possible that the apparent dissociation of the 19S regulatory particle from 
the 20S core particle in response to dasatinib treatment is merely an artifact of reduced binding 
of Rpn13 to Rpn2, and not dissociation of the entire 19S proteasome.  Subsequent studies should 
be performed with antibodies directed against other 19S subunits to confirm our results.  In 
addition, optimization of the immunoprecipitation or Native-PAGE techniques will also help 
shed light on the possible dissociation of the proteasome’s 20S and 19S particles. 
Lastly, we also observed a difference in phosphorylation of Ser152 of PI31 (PSMF1) 
after dasatinib treatment, with a reduction of 0.18 in the HT cell line and an increase of 8.91 in 
the TMD8 cell line.  PI31 is known to inhibit the proteasome by disrupting association of the 20S 
and 19S core particles (267,268,290).  To our knowledge, phosphorylation at Ser152 of PI31 has 
not been reported in previous studies, but phosphorylation at the adjacent Ser153 residue has 
been detected (271).  The role of phosphorylation at these sites is currently unknown, and 
warrants further exploration.  One could speculate that changes in phosphorylation of the PI31 
proteasome inhibitor may help cause the dissociation of the proteasome 20S and 19S particles 
that we observed, but substantially more analyses will be required to confirm this. 
Our data demonstrate a significant reduction in proteasome activity in ABC DLBCL cell 
lines after dasatinib treatment.  So far, our studies indicate that dasatinib treatment results in the 
dissociation (or decreased assembly) of the 20S core and 19S regulatory particles.  Further 
studies are needed to confirm this notion and determine the mechanism by which dasatinib 
induces this change in proteasome activity.  Focus should be placed on determining which 
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Table 3.1: Dasatinib doses used to maintain at least 75% viability 
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Table 3.2: Changes in phosphorylation of proteasome subunits after dasatinib treatment 
List of the proteasome 20S and regulatory particle subunits as well as known proteasome assembly chaperone proteins that display 
changes in phosphorylation after 30 min dasatinib treatment.  CP = core particle; RP = regulatory particle;Rpn = RP non-ATPase; pS 




Figure 3.1: Dasatinib treatment reduces proteasome activity in ABC DLBCL cells 
Proteasome (A) ChL, (B) TL, and (C) CaL activities, relative to 20S alpha7 expression and 
DMSO controls, with or without dasatinib treatment for 72 h.  Data represent the average ± S.D. 




Figure 3.2: Dasatinib-induced changes in proteasome activity are time- and dose-dependent 
(A) ChL proteasome activity after treatment with DMSO or 5 nM dasatinib at the indicated times 
in the OCI-Ly3 cell line.  (B) ChL proteasome activity after treatment with DMSO or the 





Figure 3.3: Dasatinib treatment does not alter proteasome catalytic subunit expression 
Expression of several proteasome 20S subunits from (A) isolated proteasomes or (B) whole 





Figure 3.4: Dasatinib treatment reduces 19S regulatory particle levels in isolated 
proteasomes 
(A-B) Expression of proteasome 19S Rpn13 subunits from (A) isolated proteasomes or (B) whole 
lysates after treatment with dasatinib for 72 h.  (C-D) Quantification of 19S Rpn13 expression 






Figure 3.5: Schematic of working hypothesis 
Based on our results so far, it appears that the SFKs (or other kinases) may play a role in 
stabilizing the interaction between the 20S core and 19S regulatory particles of the proteasome, 
possibly through phosphorylation of proteasome subunits.  Treatment with dasatinib may disrupt 






CHAPTER 4: PROTEASOME CATALYTIC SIGNATURES AS PREDICTORS OF 
RESPONSIVENESS TO SITE-SPECIFIC PROTEASOME INHIBITORS3 
 
4.1 Introduction 
The proteasome is a key component of cellular machinery, and is critical for maintaining 
the health and viability of a cell (173).  Acting as the garbage disposal of the cell, the proteasome 
is responsible for degrading proteins that are damaged or no longer needed.  In addition, the 
proteasome plays a role in antigen processing within the immune system (166,167).  Considering 
its essential role in a multitude of signaling pathways, such as cell cycle regulation (174), 
transcription (175), and signal transduction (176), it is not surprising that aberrant proteasome 
activity is linked with disease.  For example, proteasome activity is often upregulated in cancer 
(172,177,178), but downregulated in neurodegenerative diseases (179).  Consequently, there has 
been and continues to be a high level of interest in the proteasome as a therapeutic target. 
The proteasome is a multi-subunit protein comprised of a 20S core particle and a 
regulatory cap particle.  The 20S core particle is a barrel-shaped structure that harbors the 
protein’s proteolytic activity.  It is comprised of two outer α-rings and two inner β-rings.  The 
core particle has three distinct proteolytic activities: caspase-like (CaL), trypsin-like (TL), and 
chymotrypsin-like (ChL), which are provided by its β1, β2, and β5 subunits, respectively (163).  
In immune cells, or in nonimmune cells in the presence of interferon or tumor necrosis factor, 
each of these subunits can be replaced by immunoproteasome subunits β1i, β2i, and β5i, 
respectively, resulting in either mixed proteasomes, with one or two subunits replaced, or the full 
                                                 
3 This chapter is in preparation to be submitted to an academic journal.  The original citation is as follows: 
Cann ML, Wang Q, Lawrence DS, Priestman MA. Proteasome catalytic signatures as predictors of responsiveness 
to site-specific proteasome inhibitors. In preparation. 
 
109 
immunoproteasome when all three are substituted (163,165).  This produces a proteasome with 
altered cleavage patterns favoring the production of peptides involved in antigen presentation 
(163,166,167).  Whereas the proteasome’s 20S core particle acts as the degradation machinery, 
the regulatory particles serve as a lid to the 20S core particle and facilitate binding, unfolding, 
and entry of proteasome substrates.  There are four different regulatory particles that can bind to 
the 20S core particle: PA700 (also known as 19S), PA28αβ, PA28γ, and PA200 (163).  
Considering the variety of regulatory particles and catalytic 20S subunits, there is potential for 
several forms of the proteasome to exist within a given tissue, or even within an individual cell 
(171,172). 
There are currently three proteasome inhibitors approved for clinical use: bortezomib, 
carfilzomib, and ixazomib (182).  All three are used for the treatment of multiple myeloma (and 
mantle cell lymphoma in the case of bortezomib), and are currently in clinical trials for other 
hematological and solid malignancies.  These inhibitors preferentially target the β5 subunit of the 
proteasome, which confers the proteasome’s ChL activity (183-185).  Although these inhibitors 
are successful in the clinic, bortezomib is known to have numerous side effects, the most 
significant of which is peripheral neuropathy.  Furthermore, there are many patients who are 
inherently resistant or develop resistance to the current proteasome inhibitors (291,292).  This 
resistance has been ascribed to mutations in the β5 subunit or increased proteasome expression, 
and has the potential to be overcome by targeting multiple catalytic subunits (175,176).  In an 
effort to combat drug resistance and unwanted side effects, a new generation of proteasome 
inhibitors that target the β2 (LU-102) (293) and β1 (NC-001) (294) subunits have been 
described.  These β2 (TL) and β1 (CaL) inhibitors, while not reported to be cytotoxic alone in 
several cancer cell lines, do increase the susceptibility of these cells to β5 inhibitors (293-297).  
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Optimized combinations of site-specific proteasome inhibitors have the potential to increase the 
efficacy as well as reduce side effects of β5 inhibitors due to lower doses needed for clinical 
effectiveness.  However, combination studies of these inhibitors have been primarily limited to 
multiple myeloma cell lines and patient samples, and there are currently no means for predicting 
which cell types will be sensitive to these inhibitors.  We sought to explore the sensitivity of a 
panel of cancer cell lines to the TL and CaL proteasome inhibitors.  Furthermore, we addressed 
whether there is a biochemical marker, such as proteasome subunit expression or activity, that 
could predict which cell types would be most sensitive to these inhibitors.  Herein, we report that 
cell lines that have low TL and CaL activities relative to ChL activity are particularly sensitive to 
TL and CaL inhibitors, respectively, especially when employed in combination with ChL-
targeted inhibitors. 
 
4.2 Materials and Methods 
4.2.1 Materials 
Farage, HL60, HeLa, A549, MCF7 and DU145 cell lines were obtained from the tissue 
culture facility at the University of North Carolina at Chapel Hill.  All reagents for cell culture 
media were purchased from Gibco. CellTiter-Glo® 2.0 was purchased from Promega.  
Bortezomib and carfilzomib were purchased from Enzo life sciences.  LU-12 and NC-001 were 
gifts from Dr. H. Overkleeft at the University of Leiden in the Netherlands.  The BCA kit from 
Thermo Scientific was used to quantify the protein content of all lysates.  M-PER and Halt-
protease cocktail were from Thermo-Fisher.  All other chemicals were from Fisher or Sigma 
unless otherwise noted. 
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4.2.2 Cell Culture 
HeLa, A549, MCF7 and DU145 cell lines were passaged by treatment with 0.05% trypsin 
+ 0.53 mM EDTA before reaching confluence and maintained in DMEM containing 10% fetal 
bovine serum (FBS), non-essential amino acids and penicillin-streptomycin at 37 °C in a 5% 
CO2 incubator.  Farage and HL60 cell lines were maintained between 3x10
5 – 1x106 in RPMI 
1640 media containing 15% FBS supplemented with penicillin-streptomycin at 37 °C in a 5% 
CO2 incubator. 
4.2.3 Proteasome Enriched Cell Extracts 
One 90% confluent 75 cm2 flask of HeLa, A549, MCF7 or DU145 cell lines or 50 mL of 
Farage or HL60 cell lines at 6x105 were used to isolate a cell fraction to monitor proteasome 
activity while removing other protease activity (213,264).  Isolated cells were resuspended in ice 
cold PBS, centrifuged at 1,000 x g for 5 min at 4 °C for 3 cycles.  Cells were then resuspended in 
4 volumes homogenization buffer (50 mM Tris, 250 mM sucrose, 5 mM MgCl2, 1 mM ATP, 1 
mM DTT, 0.5 mM EDTA, pH 7.5) with 0.025% digitonin, incubated on ice for 10 min, followed 
by centrifugation at 17,000 x g for 10 min at 4 °C.  The supernatant was then ultracentrifuged at 
180,000 x g for 4 h at 4 ˚°C.  The supernatant was removed and the pellet resuspended in 
homogenization buffer without digitonin.  Protein concentration was determined using the BCA 
kit from Thermo Scientific. 
4.2.4 Assessment of Proteasome Activity 
The activities of all proteasome enriched extracts were determined in assay buffer (50 
mM Tris pH 7.5, 40 mM KCl, 4 mM MgCl2, 1 mM ATP, 1 mM EDTA) and 0.05% bovine 
serum albumin (BSA) (213,264) with 0.5 µM ChL-488, 1 µM TL-550, and 1 µM CaL-633 
proteasome sensors.  The reactions were initiated with 10 µg of sample and the reaction progress 
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monitored for 2 h at room temperature.  Control assays without proteasome were run to ensure 
that the fluorescent change was due to proteasome activity and not hydrolysis.  Fluorescence was 
monitored on Molecular Devices Spectra Max Gemini EM plate reader with excitation at 490 
nm, 550 nm, and 625 nm with emission at 515 nm, 575 nm, and 655 nm, respectively.  
Sigmaplot 12 (serial number 775206611) was used for the analysis of all data.  The rate of each 
assay was determined using a linear fit to the first 10% of substrate consumption.  All data is 
reported as the mean ± standard deviation of triplicate assays where FU is fluorescent units. 
4.2.5 Western Blots 
Proteasome 20S α7, 19S Rpn13, PA28α, and ubiquitin antibodies were purchased from 
Cell Signaling Technologies.  Proteasome 20S β1, 20S β2, and 20S β5 antibodies were 
purchased from Enzo Life Sciences.  Proteasome 20S β1i and 20S β5i antibodies were purchased 
from Thermo Fisher Scientific.  Proteasome 20S β2i and PA200 antibodies were purchased from 
Novus Biologicals.  All secondary antibodies were purchased from GE Healthcare.  SDS-PAGE 
was performed using 4-15% SDS Tris-HCl gels (Bio-Rad) and loading 20 μL of each sample per 
well.  Gels were then transferred to polyvinylidene fluoride (PVDF) membranes overnight at 4 
°C.  Membranes were blocked with 5% BSA in 1X Tris-buffered saline (TBS) + 0.1% Tween-20 
for 2 h, then incubated with 1:500-1:1000 of the primary antibody in the blocking solution 
overnight at 4 °C.  Membranes were washed with TBS + 0.1% Tween-20, incubated with 1:5000 
HRP-conjugated secondary antibody for 1 h at room temperature, and washed again with TBS + 
0.1% Tween-20.  Secondary antibodies were detected using the Clarity Western ECL Substrate 
(Bio-Rad) according to the manufacturer’s protocol.  Images were acquired using an Alpha 
Innotech FluorChem FC2 using the chemiluminescent settings. 
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4.2.6 Cell Viability Studies 
CellTiter-Glo® 2.0 was used to monitor cell viability according to published Promega 
protocols.  Inhibitors concentration for the viability assays were 0-400 nM bortezomib, 0-400 
nM carfilizomib, 0-5000 nM NC-001, and/ or 0-5000 nM LU-102.  All inhibitors were dissolved 
in DMSO with a final concentration of DMSO of 1% in every well.  Cells were plated at 2,000 
cell/well in a 96 well plate with 100 μl media +/- inhibitors and grown for 48 h at 37 °C in a 5% 
CO2 incubator.  After incubation 100 μl of CellTiter-Glo® 2.0 was added to each well and 
incubated at room temperature for 30 min.  The plates were read on the Molecular Devices 
Spectra Max Gemini EM plate reader with the luminescent settings.  All data is reported as the 
mean ± standard deviation of triplicate assays.  All data was fit to the standard IC50 equation and 
plotted using Sigmaplot. 
4.2.7 Proteasome Inhibition and Total Ubiquitination 
All inhibitors were dissolved in DMSO with a final concentration of DMSO of 1% in 
every well.  Inhibitor concentrations for the viability assays were 5 nM bortezomib, 50 nM 
carfilizomib, 500-5000 nM NC-001, or 500-5000 nM LU-102.  Cells were plated at 50,000 
cell/well in 2 ml media in a 6 well plate and grown overnight at 37 °C in a 5% CO2 incubator.  
Inhibitors were added to the media and the plates were incubated at 37 °C in a 5% CO2 incubator 
for 6 h.  The media was removed and the cells were washed with PBS before lysis with MPER + 
Halt protease cocktail.  Western blots were run as previously described. 
4.2.8 Correlation Assessments 
Correlation assessments were performed using the Pearson’s correlation coefficient, 
Spearman’s rank correlation coefficient, or Kendall’s rank correlation coefficient.  The Pearson’s 
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where 𝑥 and 𝑦 are the datasets being compared (𝑥𝑖 being an individual data point and ?̅? being the 
mean of dataset 1, and analogously for 𝑦𝑖 and ?̅?) and 𝑛 is the total number of data points in each 
set (i.e. the number of cell lines).  The Spearman’s rank correlation coefficient was determined 
by first assigning the values in each dataset a rank (1-6), where the smallest value was assigned a 
rank of 1 and the largest a rank of 6.  The Pearson’s correlation equation was then applied to the 
ranked values of each dataset to give the Spearman’s rank correlation coefficient (ρ).  The 
Kendall’s rank correlation coefficient was determined using the same ranking system described 







where 𝐶 is the number of concordant (𝑥, 𝑦) pairs from dataset 𝑥 and dataset 𝑦, 𝐷 is the number 
of discordant (𝑥, 𝑦) pairs from dataset 𝑥 and dataset 𝑦, and 𝑛 is the total number of data points in 
each set (i.e. the number of cell lines). 
 
4.3 Results and Discussion 
4.3.1 Sensitivity to Site-Specific Proteasome Inhibitors 
Bortezomib and carfilzomib are two proteasome inhibitors that are clinically approved 
for the treatment of multiple myeloma.  Both bortezomib and carfilzomib preferentially target the 
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ChL activity of the proteasome (183-185).  However, due to significant side effects and the 
development of resistance to these inhibitors, there have also been efforts to develop inhibitors 
that selectively target the TL and CaL sites, such as the TL inhibitor LU-102 (293) and the CaL 
inhibitor NC-001 (294).  In the current study, we sought to examine the sensitivity of several 
cancer cell lines to site-specific proteasome inhibitors, and to determine if there is a marker that 
can predict inhibitor sensitivity.  The cell lines used were: Farage, a B-cell lymphoma cell line; 
HL60, a leukemia cell line; HeLa, a cervical cancer cell line; A549, a lung carcinoma cell line; 
DU145, a prostate cancer cell line; and MCF7, a breast adenocarcinoma cell line.  We began by 
generating dose-response curves with bortezomib, carfilzomib, LU-102, and NC-001 for our 
panel of cell lines to determine each cell line’s sensitivity to the various compounds (Table 4.1, 
Figure 4.1).  However, due to solubility issues with LU-102 and NC-001, we were unable to 
determine EC50s for several of the cell lines, and instead report the percent viability of each cell 
line at 5 μM of each compound.  EC50 values that could be determined for NC-001 and LU-102 
are reported in Table 4.2.  The six cell lines respond similarly to bortezomib and carfilzomib, 
with EC50 values ranging from about 3 nM to 30 nM for bortezomib and about 10 nM to 70 nM 
for carfilzomib.  The cell lines display a wider range of sensitivities to the TL and CaL inhibitors 
LU-102 and NC-001, respectively, with percent viabilities at 5 μM ranging from 4% to 100% for 
LU-102 and 26% to 100% for NC-001, respectively.  Although previous studies have reported 
synergy of LU-102 and NC-001 with ChL inhibitors, only limited single-agent toxicities have 
been described for these compounds to date (293,294,296,297).  We discovered that the TL 
inhibitor LU-102 and CaL inhibitor NC-001 alone are cytotoxic in several cell lines, indicating 
their potential use for cancer treatment in the clinic. 
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 To determine if LU-102 or NC-001 resistance by some cell lines is due to lack of cellular 
proteasome inhibition, we investigated total protein ubiquitination.  Proteins are targeted for 
degradation by the proteasome by labeling with ubiquitin chains (163).  Consequently, an 
accumulation of ubiquitin is indicative of proteasome inhibition.  We assessed ubiquitin 
accumulation in response to the various site-specific proteasome inhibitors (Figure 4.2).  Short-
term treatment of cells with bortezomib or carfilzomib produced ubiquitin accumulation in all 
cell lines.  Interestingly, the TL inhibitor LU-102 and CaL inhibitor NC-001 induce ubiquitin 
accumulation in all cell lines at a concentration of 5 μM.  This indicates that the site-specific 
proteasome inhibitors are penetrating all of the cancer cell lines tested and inhibiting proteasome 
activity, even if this inhibition does not produce a cytotoxic effect. 
4.3.2 Proteasome Subunit Expression and Inhibitor Sensitivity 
Our dose-response curve data demonstrate that the sensitivity to TL and CaL proteasome 
inhibitors varies among our cell lines.  However, methods for predicting these sensitivities have 
yet to be explored.  To determine if there is a biochemical marker that can predict site-specific 
proteasome inhibitor sensitivity, we first examined the expression of the proteasome’s 20S 
catalytic subunits (β1, β2, β5, β1i, β2i, and β5i).  We also assessed the presence of the 
proteasome’s regulatory particle subunits (19S/PA700, PA28, or PA200), as binding of the 
regulatory particles is known to enhance proteasome activity (265,266).  We found that both 
proteasome catalytic subunit expression and regulatory particle expression varies among the six 
cell lines (Figure 4.3).  To determine if expression of any of these proteins correlates with site-
specific proteasome inhibitor sensitivity, we assessed possible relationships using the Pearson’s 
correlation method, the Spearman’s rank correlation method, and the Kendall’s rank correlation 
method (Tables 4.3 and 4.4).  We found that neither proteasome 20S catalytic subunit expression 
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nor regulatory particle subunit expression correlate with sensitivity to any of the proteasome 
inhibitors.  Therefore, proteasome protein expression is not a suitable biomarker for predicting 
inhibitor sensitivity. 
4.3.3 Proteasome Catalytic Activity and Inhibitor Sensitivity 
Moving forward in our search for predictors of proteasome inhibitor sensitivity, we next 
considered the individual activities of the ChL, TL, and CaL proteasome subunits.  The subunit 
composition and activity of the proteasome has been found to vary depending on the type of 
malignancy, as was observed in a recent study describing differences in expression of the β-
subunits in acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) cell 
lines (298).  Additionally, total activity of the ChL, TL, and CaL sites differs due to proteasome 
composition, tissue type, or disease state (202,298).  For example, some studies suggest that ChL 
activity is higher in cancerous cells lines relative to normal cells (172,299).  However, Driessen 
and colleagues failed to observe any correlation between ChL activity and cancer in leukemia 
patients (300).  In these previous reports, proteasome activity was monitored by methods that 
precluded simultaneous real-time monitoring of all three catalytic activities.  We’ve designed a 
set of internally quenched fluorescent peptides that enable simultaneous monitoring of the ChL, 
TL, and CaL activities of the proteasome (Figure 4.4) (213).  These proteasome sensors possess 
photochemically distinct fluorophores: fluorescein (λex = 488 nm) for ChL, 
tetramethylrhodamine (λex = 550 nm) for TL, and DyLight633 (λex = 633 nm) for CaL, appended 
to the N-terminus of the recognition sequences selective for each proteasomal activity [ChL: 
Fluorophore-His-His-Ser-Leu-Lys(Quencher); TL: Fluorophore-Leu-Arg-Arg-Lys(Quencher); 
CaL: Fluorophore-norLeu-Pro-norLeu-Asp-Lys(Quencher)].  A broad-spectrum quencher, an 
acid blue 40 derivative (AB40) (214), is appended to the C-terminal lysine residue on each 
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sensor.  Proteolysis liberates the fluorophore from the quencher and furnishes a fluorescent 
enhancement of 30- to 140-fold for each peptide. 
Using our proteasome sensor triad, we assessed the relative activities of the ChL, TL, and 
CaL proteasome subunits in each of our cell lines (Figure 4.5a, Figure 4.6).  Although the 
relative catalytic activities vary across the six cell lines, the ChL activity is consistently higher 
than the TL and CaL activities in all cell lines.  Indeed, many investigators believe that ChL 
activity is most important for protein degradation, and higher levels of ChL activity relative to 
TL and CaL activities have been observed in previous studies (213,301).  However, it should be 
noted that the importance of the TL and CaL activities is gaining recognition (294,295,301,302).  
To this end, we next determined if any correlations exist between proteasome activity and 
inhibitor sensitivity (Tables 4.3 and 4.5).  Similar to protein expression, proteasome activity does 
not correlate with inhibitor sensitivity.  Thus, proteasome activity is also not a suitable biomarker 
for predicting inhibitor sensitivity.  Furthermore, proteasome protein expression levels do not 
correlate with subunit activity (Table 4.6, Figure 4.7), indicating that protein expression does not 
always reflect enzymatic activity.  This furthers the notion that activity, not protein level, is a key 
consideration when contemplating the use of an inhibitor. 
4.3.4 Proteasome Catalytic Signature and Inhibitor Sensitivity 
In our previous work, we found that the proteasome has a unique “catalytic signature” (or 
ratio of catalytic activities) depending on cell type, source, or disease state (213).  We therefore 
questioned whether the proteasome’s catalytic signature could serve as a predictor of proteasome 
inhibitor sensitivity.  We determined the catalytic signature of each cell line by calculating the 
TL/ChL, CaL/ChL, and TL/CaL activity ratios (Figure 4.5b, Figure 4.8), which are independent 
of the amount of proteasome in each sample, and therefore provide a consistent and reliable 
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measurement that can be compared between samples.  These individual catalytic ratios vary 
across the six cell lines.  In the case of TL/CaL, the ratio is as low as 0.2 in Farage and as high as 
1 in DU145.  By contrast, the dynamic range of the TL/ChL and CaL/ChL ratios is narrower, 
given the prominent ChL activity in all cell lines.  Nonetheless, these ratios vary as well, with the 
hematological cell lines (Farage and HL60) at the low end and the solid tumors (HeLa, DU145, 
and MCF7) at the high end.  We then assessed the correlation between the proteasome’s catalytic 
signature and proteasome inhibitor sensitivity (Table 4.3, Table 4.7), and found that the ratios of 
the catalytic activities do correlate with site-specific inhibitor sensitivity.  All three correlation 
methods reveal that the TL/ChL ratio is significantly positively correlated with cell viability after 
treatment with the TL inhibitor LU-102 (Pearson: 0.979; Spearman: 1.000; Kendall: 1.000; 
Tables 4.3 and 4.7, Figure 4.9a).  Likewise, the CaL/ChL ratio is significantly positively 
correlated with cell viability after treatment with the CaL inhibitor NC-001 (Pearson: 0.892; 
Spearman: 1.000; Kendall: 1.000; Tables 4.3 and 4.7, Figure 4.9b).  These data indicate that, 
although proteasome activities and subunit expression levels do not predict sensitivity to site-
specific inhibitors, the TL/ChL and the CaL/ChL ratios of proteasome activity do serve as 
barometers of sensitivity to the TL inhibitor LU-102 and the CaL inhibitor NC-001, respectively.  
In particular, the lower the proteasomal TL/ChL ratio in a given cell line, the more sensitive that 
cell line will be to the TL inhibitor LU-102.  An analogous relationship is observed for the 
CaL/ChL ratio and the CaL inhibitor NC-001.  In short, these results are consistent with the 
notion that, in spite of the depressed CaL and TL proteolytic activities in certain cell lines, these 
activities remain essential to cell viability.  It is tempting to speculate that drug sensitivity is 
accentuated under conditions in which the targeted pathway is catalytically subdued.  It is 
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possible that, in these cells, there are key protein targets that require TL- or CaL-mediated 
degradation in order for the cell to survive. 
4.3.5 Synergy of ChL and TL or CaL Site-Specific Inhibitors 
Previous studies have demonstrated synergy between TL or CaL inhibitors and ChL 
inhibitors (293-295,297).  However, these studies have been primarily limited to hematological 
cells, particularly those derived from multiple myeloma.  Considering our observations of single-
agent cytotoxicity of LU-102 and NC-001, we next sought to explore the potential synergy 
between the site-specific TL and CaL inhibitors and the commercially available proteasome 
inhibitors bortezomib (Table 4.8, Figure 4.10) and carfilzomib (Table 4.9, Figure 4.11) in our 
panel of cell lines.  Both of these inhibitors target the ChL site in proteasomes.  The addition of 
the TL inhibitor LU-102 induces up to a 12-fold decrease in bortezomib EC50 values.  Only the 
MCF7 cell line, which displays the largest TL/ChL ratio, is resistant to the synergistic impact of 
LU-102.  In an analogous vein, the CaL inhibitor NC-001 reduces the EC50 of bortezomib, albeit 
not to the same extent as LU-102.  However, with both inhibitors, the cell lines with the lowest 
TL/ChL and CaL/ChL ratios display the greatest synergy.  We also examined the impact of NC-
001 and LU-102 on the efficacy of carfilzomib (Table 4.9).  Once again, cell lines with low 
TL/ChL and CaL/ChL ratios are significantly more susceptible to combination therapy than the 
corresponding cell lines with more robust relative TL and CaL activities.  Our data demonstrate 
that the LU-102 and NC-001 site-specific proteasome inhibitors display synergy with ChL 
proteasome inhibitors.  Interestingly, the TL inhibitor LU-102 generates a more robust 
synergistic effect with both bortezomib and carfilzomib than the CaL inhibitor NC-001, a 
phenomenon that has also been observed in a previous study (297).  These results, along with the 
single-agent sensitivities described above, suggest that cell lines with low TL and CaL 
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proteasome activities relative to ChL activity are nonetheless dependent upon these activities for 
survival. 
4.3.6 Conclusions 
The proteasome serves as the major degradation machinery for cellular proteins, and 
plays an important role in many cellular processes.  It is a validated anticancer target, and the 
current clinically approved proteasome inhibitors primarily target its ChL activity.  Although 
studies have shown that targeting the TL or CaL activity can sensitize cells to ChL inhibition, 
these studies have been primarily limited to hematological cell lines.  We have assessed 
inhibitors of TL and CaL activity in a variety of cancer cell lines, and found both inhibitors 
capable of single-agent cytotoxicity, with a range of sensitivities among the different cell lines.  
We have determined that neither proteasome subunit expression nor TL, CaL, or ChL activity 
correlate with sensitivity to proteasome inhibitors.  However, the ratios of the catalytic activities 
do correlate with site-specific inhibitor sensitivity.  Cells with the lowest TL/ChL and CaL/ChL 
activity ratios are most sensitive to the TL and CaL site-specific inhibitors, respectively.  
Furthermore, synergy between TL or CaL inhibitors and bortezomib or carfilzomib is evident in 
all of the cell lines we studied, and is particularly strong for the hematological cell lines. 
Contemporary cancer therapies are typically designed to disrupt the action of upregulated 
biochemical targets.  However, our results show it is also important to consider more modest 
biochemical activities that are nonetheless crucial.  In short, a transformed cell’s addiction to 
certain prioritized biochemical actions might render it susceptible to the interference of related, 
but significantly less robust, activities.  In the case of the proteasome, cell lines that prioritize 
ChL proteasome activity over TL and CaL activity are particularly sensitive to TL and CaL 
inhibitors, especially when employed in combination with ChL-targeted inhibitors.  These cells 
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have very little TL and CaL activities to start, and it is clear that what little activity they do have 
is crucial for cell survival.  Moreover, although the current approvals and clinical trials for 
proteasome inhibitors focus mainly on hematological malignancies, our study demonstrates the 


















Farage 3.6 ± 0.1 27.6 ± 5.5 4.2 ± 0.8 26.6 ± 5.9 
HL60 4.2 ± 0.1  10.8 ± 2.9  28.5 ± 4.3  58.7 ± 16.5  
HeLa 5.6 ± 0.1 61.6 ± 2.0 62.0 ± 3.3 90.7 ± 2.5 
A549 5.7 ± 0.1 38.3 ± 4.0 44.7 ± 2.7 48.4 ± 3.1 
DU145 31.2 ± 4.0 61.0 ± 4.8 101.3 ± 5.3 94.2 ± 2.4 
MCF7 25.2 ± 1.9 67.5± 3.9 89.8 ± 11.4 100.6 ± 4.8 
 
Table 4.1: Cell viability of cancer cell lines when exposed to single proteasome inhibitors 
For bortezomib and carfilzomib, data are reported as EC50 ± S.D.  For LU-102 and NC-001, data 
are reported as % viability ± S.D. at 5 μM inhibitor.  Solubility issues with the compounds 









Farage 600 ± 50 1200 ± 140 
HL60 1780 ± 210  > 5000 
HeLa > 5000 > 5000 
A549 3910 ± 100 4970 ± 120 
DU145 > 5000 > 5000 
MCF7 > 5000 > 5000 
 
Table 4.2: Cell viability of cancer cell lines when exposed to the proteasome inhibitors LU-
102 or NC-001 













TL CaL ChL TL/ChL CaL/ChL TL/CaL 
LU-102 -0.05 -0.71 0.14 0.20 -0.83 -0.80 0.99 0.82 0.72 
NC-001 -0.35 -0.69 -0.16 -0.13 -0.83 -0.95 0.82 0.96 0.45 
 
Table 4.3: Correlation between proteasome activity, catalytic signatures, and subunit 
expression with site-specific inhibitor toxicity 
Data are reported as the average of Pearson’s, Spearman’s, and Kendall’s correlation 
coefficients.  A coefficient equal to 1 indicates positive correlation, equal to 0 indicates no 
correlation, and equal to -1 indicates negative correlation.  A correlation coefficient greater than 










β2 (TL) β1 (CaL) β5 (ChL) 
LU-102 
Pearson’s -0.012 -0.760 0.007 
Spearman’s -0.086 -0.771 0.200 
Kendall’s -0.067 -0.600 0.200 
NC-001 
Pearson’s -0.297 -0.710 -0.208 
Spearman’s -0.429 -0.771 -0.200 
Kendall’s -0.333 -0.600 -0.067 
Bortezomib 
Pearson’s -0.002 -0.834 -0.196 
Spearman’s 0.143 -0.657 0.314 
Kendall’s 0.067 -0.467 0.333 
Carfilzomib 
Pearson’s -0.278 -0.851 -0.035 
Spearman’s -0.543 -0.886 -0.143 
Kendall’s -0.467 -0.733 -0.200 
 
Table 4.4: Correlation between proteasome subunit expression and inhibitor toxicity 
Data are reported as the correlation coefficient for each correlation test.  A coefficient equal to 1 
indicates positive correlation, equal to 0 indicates no correlation, and equal to -1 indicates 
negative correlation.  A correlation coefficient greater than or equal to 0.89 (or less than or equal 









TL CaL ChL 
LU-102 
Pearson’s 0.185 -0.859 -0.795 
Spearman’s 0.200 -0.886 -0.886 
Kendall’s 0.200 -0.733 -0.733 
NC-001 
Pearson’s -0.118 -0.925 -0.848 
Spearman’s -0.200 -0.829 -1.000 
Kendall’s -0.067 -0.733 -1.000 
Bortezomib 
Pearson’s 0.093 -0.628 -0.509 
Spearman’s 0.314 -0.714 -0.771 
Kendall’s 0.333 -0.600 -0.600 
Carfilzomib 
Pearson’s 0.043 -0.589 -0.505 
Spearman’s -0.143 -0.600 -0.771 
Kendall’s -0.200 -0.333 -0.600 
 
Table 4.5: Correlation between proteasome activity and inhibitor toxicity 
Data are reported as the correlation coefficient for each correlation test.  A coefficient equal to 1 
indicates positive correlation, equal to 0 indicates no correlation, and equal to -1 indicates 
negative correlation.  A correlation coefficient greater than or equal to 0.89 (or less than or equal 










TL CaL ChL 
β1 
Pearson - 0.429 - 
Spearman - 0.600 - 
Kendall - 0.333 - 
β2 
Pearson 0.900 - - 
Spearman 0.829 - - 
Kendall 0.733 - - 
β5 
Pearson - - -0.164 
Spearman - - 0.200 
Kendall - - 0.067 
 
Table 4.6: Correlation between proteasome activity and subunit expression 
Data are reported as the correlation coefficient for each correlation test.  A coefficient equal to 1 
indicates positive correlation, equal to 0 indicates no correlation, and equal to -1 indicates 
negative correlation.  A correlation coefficient greater than or equal to 0.89 (or less than or equal 








TL/ChL CaL/ChL TL/CaL 
LU-102 
Pearson’s 0.979 0.851 0.776 
Spearman’s 1.000 0.886 0.771 
Kendall’s 1.000 0.733 0.600 
NC-001 
Pearson’s 0.857 0.892 0.583 
Spearman’s 0.886 1.000 0.429 
Kendall’s 0.733 1.000 0.333 
Bortezomib 
Pearson’s 0.910 0.733 0.674 
Spearman’s 0.943 0.771 0.829 
Kendall’s 0.867 0.600 0.733 
Carfilzomib 
Pearson’s 0.744 0.722 0.499 
Spearman’s 0.771 0.771 0.429 
Kendall’s 0.600 0.600 0.200 
 
Table 4.7: Correlation between proteasome catalytic signatures and inhibitor toxicity 
Data are reported as the correlation coefficient for each correlation test.  A coefficient equal to 1 
indicates positive correlation, equal to 0 indicates no correlation, and equal to -1 indicates 
negative correlation.  A correlation coefficient greater than or equal to 0.89 (or less than or equal 













Farage 12 ± 0.4 N.D. 4.5 ± 0.2 N.D. 
HL60 4.7 ± 0.2 N.D. 1.1 ± 0.1 6.0 ± 0.2 
HeLa 1.1 ± 0.3 9.3 ± 0.2 1.1 ± 0.1 2.8 ± 0.1 
A549 1.7 ± 0.1 7.1 ± 0.4 2.1 ± 0.1 2.1 ± 0.1 
DU145 1.5 ± 0.1 5.0 ± 0.3 1.3 ± 0.2 1.3 ± 0.1 
MCF7 1.3 ± 0.2 1.8 ± 0.2 1.1 ± 0.2 1.1 ± 0.2 
 
Table 4.8: Synergy of site-specific inhibitors with bortezomib 
Fold decrease in EC50 of cell viability of cancer cell lines when exposed to bortezomib ± NC-001 













Farage 15 ± 0.1 N.D. 8.0 ± 0.1 N.D. 
HL60 6.5 ± 0.1 N.D. 1.0 ± 0.1 12 ± 0.1 
HeLa 1.5 ± 0.1 17 ± 0.1 1.3 ± 0.3 7.0 ± 0.3 
A549 1.7 ± 0.1 12 ± 0.1 2.1 ± .02 9.7 ± 0.1 
DU145 1.2 ± 0.1 5.1 ± 0.4 1.2 ± 0.1 6.1 ± 0.1 
MCF7 1.2 ± 0.1 2.2 ± 0.2 1.2 ± 0.1 2.4 ± 0.2 
 
Table 4.9: Synergy of site-specific inhibitors with carfilzomib 
Fold decrease in EC50 of cell viability of cancer cell lines when exposed to carfilzomib ± NC-001 






Figure 4.1: Dose-response curves of cell viability of cancer cell lines when exposed to the 
proteasome inhibitors 
Inhibitors: (A) bortezomib, (B) carfilzomib, (C) LU-102, and (D) NC-001.  Cell lines: Farage 
(black), HL60 (red), HeLa (green), A549 (yellow), DU145 (blue), and MCF7 (pink).  All assays 





Figure 4.2: Western blots for total ubiquitination in cancer cell lines ± proteasome 
inhibitors 
Lane 1: no inhibitor, lane 2: 5 nM bortezomib, lane 3: 50 nM carfilzomib, lane 4: 500 nM LU-
102, lane 5: 5000 nM LU-102, lane 6: 500 nM NC-001, lane 7: 5000 nM NC-001.  Cell lines: (A) 
Farage, (B) HL60, (C) HeLa, (D) A549, (E) DU145, and (F) MCF7.  Cells were treated ± 





Figure 4.3: Proteasome protein expression from various cancer cell lines 
(A) Western blots of several proteasome subunits from the core particle and regulatory particles.  
(B-D) Quantification of western blots for (B) regular 20S core particle subunits, (C) 
immunoproteasome 20S core particle subunits, and (D) different regulatory particle subunits.  






Figure 4.4: Schematic of proteasome sensors 






Figure 4.5: Proteasome catalytic activity from various cancer cell lines 
(A) Site-specific activity of proteasome from cancer cell lines with ChL (black), TL (grey) and 
CaL (white) activity sensors.  Activity is represented as relative activity compared to the amount 
of α7 proteasome subunit present in each sample.  (B) Proteasome catalytic signatures, ratio of 
TL:ChL (black), CaL:ChL (grey), and TL:CaL (white) vary in different cancer cell lines.  All 





Figure 4.6: Proteasome catalytic activities 
Site-specific ChL (A), TL (B), and CaL (C) proteasome activities from cancer cells.  Activity is 
represented as relative activity standardized to the amount of α7 proteasome subunit present in 
each sample.  Data represent the average ± S.D. of 4-5 proteasome preparations and triplicate 





Figure 4.7: Lack of correlation between proteasome activity and subunit expression 
Comparison of site-specific ChL (A), TL (B), and CaL (C) proteasome activities to β5 (A), β2 






Figure 4.8: Proteasome catalytic ratios 
Ratios of TL:ChL (A), CaL:ChL (B), and TL:CaL (C) proteasome activities vary in different 
cancer cell lines.  Data represents the average ± S.D. of 4-5 proteasome preparations and 





Figure 4.9: Correlation of proteasome inhibitor sensitivity vs. catalytic activity ratios 
(A) Graph of TL inhibitor viability (percent viability of cells after treatment with 5 μM LU-102) 
vs. TL/ChL proteasome activity ratio.  (B) Graph of CaL inhibitor viability (percent viability of 





Figure 4.10: Synergy between site-specific proteasome inhibitors and bortezomib 
Dose-response curves of cell viability of cancer cell lines when exposed to bortezomib (black) ± 
NC-001 (red = 150 nM, green = 2000 nM) or LU-102 (yellow = 75 nM, blue = 2000 nM).  Cell 
lines: (A) Farage, (B) HL60, (C) HeLa, (D) A549, (E) DU145, and (F) MCF7.  All assays were 





Figure 4.11: Synergy between site-specific proteasome inhibitors and carfilzomib 
Dose-response curves of cell viability of cancer cell lines when exposed to carfilzomib (black) ± 
NC-001 (red = 150 nM, green = 2000 nM) or LU-102 (yellow = 75 nM, blue = 2000 nM).  Cell 
lines: (A) Farage, (B) HL60, (C) HeLa, (D) A549, (E) DU145, and (F) MCF7.  All assays were 





CHAPTER 5: CONCLUDING REMARKS 
 
5.1 Summary 
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, with at least one-
third of its patients not responding to the current chemotherapy regimen, R-CHOP.  By gene 
expression profiling, patients with DLBCL can be categorized into two clinically relevant 
subtypes: activated B-cell (ABC) DLBCL and germinal center B-cell (GCB).  Patients with ABC 
DLBCL have a worse prognosis, and are defined by chronic, overactive signaling through the B-
cell receptor and NF-κB pathways.  These pathways are heavily dependent upon the Src family 
kinases (SFKs) for their signaling, and the NF-κB pathway is also dependent upon the 
proteasome for its signaling.  The purpose of my thesis work was to identify additional 
therapeutic targets for the treatment of DLBCL, namely the ABC subtype, and we chose to focus 
on the SFKs and the proteasome as potential drug targets for this disease. 
In Chapter 2, we examined the effects of the SFK inhibitor dasatinib in a panel of ABC 
and GCB DLBCL cell lines, and found that the ABC DLBCL cell lines are much more sensitive 
to dasatinib than the GCB DLBCL cell lines.  However, using multiplexed inhibitor bead 
coupled to mass spectrometry (MIB/MS) kinome profiling and western blot analysis, we found 
that both subtypes display inhibition of the SFKs in response to dasatinib after both short- and 
long-term treatment.  The MIB/MS analyses revealed several cell cycle kinases, including 
CDK4, CDK6, and the Aurora kinases, are downregulated by dasatinib treatment in the ABC 
DLBCL subtype, but not in the GCB DLBCL subtype.  The present findings have important 
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implications for the clinical use of dasatinib for the treatment of ABC DLBCL, either alone or in 
combination with other agents. 
 In Chapter 3, we examined the effects of the SFK inhibitor dasatinib on the proteasome in 
the same panel of DLBCL cell lines.  Using a set of novel peptide probes for the proteasome’s 
three catalytic activities, we found that treatment with dasatinib results in reduced proteasome 
activity in the ABC DLBCL cell lines tested, but had no effect on the GCB DLBCL cell lines.  
Furthermore, this reduction in activity is accompanied by a reduction in the amount of 19S 
regulatory particle in isolated proteasomes.  However, the total levels of 19S regulatory particle 
are unchanged in whole lysates, indicating either a dissociation or disrupted assembly between 
the proteasome 20S core particle and 19S regulatory particle.  Furthermore, phosphoproteomics 
analyses showed several proteasome subunits and proteasome-related proteins to have changes in 
phosphorylation in response to dasatinib treatment.  This study demonstrates a potential role for 
the SFKs in regulating the proteasome, and hints at the proteasome being a potential target for 
the treatment of ABC DLBCL. 
In Chapter 4, we explored the utility of site-specific inhibitors of the proteasome’s 
trypsin-like (TL) and caspase-like (CaL) activities in a variety of cell lines.  We found that, while 
proteasome subunit expression or total activity does not correlate with proteasome activity, the 
TL/ChL and CaL/ChL ratios of proteasome activity correlate with sensitivity to TL and CaL 
inhibitors, respectively.  Furthermore, the combination of the TL or CaL site-specific inhibitors 
with bortezomib or carfilzomib is synergistic in all cell lines examined.  This suggests that the 
proteasome’s catalytic signature is useful for predicting sensitivity to site-specific inhibitors of 
the proteasome, and that dual inhibition of proteasome subunits may be a viable option for the 
treatment of both hematological and solid malignancies.  Moreover, the two cell lines that were 
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most sensitive to the site-specific proteasome inhibitors were hematological cell lines, with the 
DLBCL cell line Farage being the most sensitive overall.  It is possible that site-specific 
proteasome inhibition might be a viable treatment option for DLBCL. 
These findings have important implications for the use of dasatinib for the treatment of 
ABC DLBCL, either alone or in combination with other agents.  In addition, the proteasome also 
appears to be a promising target for the treatment of DLBCL, potentially for both subtypes. 
 
5.2 Future Directions 
The studies discussed in Chapter 2 lay the groundwork for potential uses of the SFK 
inhibitor dasatinib for the treatment of ABC DLBCL.  However, there is much that still remains 
unclear.  We have demonstrated that ABC DLBCL cell lines are more sensitive to dasatinib than 
GCB DLBCL cell lines.  Treatment with dasatinib inhibits the SFKs in both ABC and GCB 
DLBCL cell lines, and inhibits several cell cycle kinases in ABC DLBCL cell lines.  However, 
we do not know whether the inhibition of cell cycle kinases is a cause of the dasatinib sensitivity 
observed in ABC DLBCL cell lines or if it is a result of the dasatinib sensitivity.  Do the cells die 
because the cell cycle kinases are inhibited, or are the cell cycle kinases inhibited because the 
cells are dying?  Furthermore, we are still unsure of the mechanism that is leading to inhibition 
of the cell cycle kinases.  It is possible that they are inhibited due to inhibition of signaling 
pathways downstream of the SFKs, but it is also possible that the cell cycle kinases are inhibited 
due to off-target effects of dasatinib.  Future studies should explore this mechanism. 
In Chapter 3, we highlighted a potential role for the SFKs as regulators of the 
proteasome, but more studies are needed to confirm these results.  Most importantly, either 
immunoprecipitation or Native-PAGE techniques need to be optimized in order to confirm the 
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dissociation (or failure to associate) between the proteasome 20S core particle and 19S 
regulatory particle in response to dasatinib treatment.  Furthermore, additional studies are needed 
to further elucidate the mechanism by which dasatinib disrupts proteasome activity.  Some focus 
could be paid to the proteasome inhibitory protein PI31, the proteasome assembly chaperone, 
PSMG1, and the proteasome 19S subunit Rpn2, as these showed changes in phosphorylation in 
response to dasatinib treatment. 
In Chapter 4, we identified a method for predicting sensitivity to inhibitors of the β1 
(CaL) and β2 (TL) proteasome subunits.  Moreover, we found that the two hematological cell 
lines we tested had the highest sensitivity to the site-specific inhibitors.  In particular, the 
DLBCL cell line was the most sensitive.  Future studies should assess the sensitivity of our panel 
of seven DLBCL cell lines to these site-specific inhibitors, and assess potential differences in 
sensitivity between the ABC and GCB DLBCL subtypes.  We already know one GCB DLBCL 
cell line is very responsive to these inhibitors.  Will the ABC DLBCL cell lines be more 
sensitive? 
 The overall goal of this thesis work was to identify additional therapeutic agents for the 
treatment of DLBCL, and particularly the ABC DLBCL subtype.  We have found a lot of 
potential for the SFK inhibitor dasatinib, as well as potential for the site-specific proteasome 
inhibitors.  The most important future studies will entail testing these inhibitors in in vivo models 
of lymphoma, as well as human patient samples.  These compounds could be tested alone, but 
should also be tested as combination therapies with the standard of care for DLBCL, R-CHOP.  
Synergy studies between the SFK and proteasome inhibitors could also be explored.  Our hope is 
that one day, dasatinib and the site-specific proteasome inhibitors will become a routine part of 
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